Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
Patent Information
- Application Number
- TW113134398
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2023-09-14
- Filing Date
- 2024-09-11
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2044-09-10
AI Technical Summary
Current pneumococcal vaccines, such as Prevnar 13 and Vaxneuvance, do not provide adequate protection against a broad range of Streptococcus pneumoniae serotypes, particularly in regions with serotype shifts due to antibiotic resistance and varying pathogenicity, necessitating immunogenic compositions that induce immune responses against additional serotypes, especially in children under 2 years of age.
Development of adjuvanted immunogenic compositions comprising conjugated capsular saccharide antigens of Streptococcus pneumoniae, specifically conjugated via covalent or non-covalent bonds to carrier proteins, enhancing immunogenicity and inducing immune responses against additional serotypes not covered by existing vaccines.
The novel immunogenic compositions provide broad protection against Streptococcus pneumoniae serotypes, maintaining immune responses against covered serotypes while addressing serotype shifts and antibiotic resistance, particularly effective in infants and the elderly.
Smart Images

Figure TWG2TB001920316_001 
Figure TWG2TB001920316_002 
Figure TWG2TB001920316_003
Abstract
Description
Adjuvanted immunogenic compositions comprising conjugated capsular saccharide antigens of Streptococcus pneumoniae and uses thereof The present invention relates to novel adjuvanted immunogenic compositions comprising conjugated capsular saccharide antigens of Streptococcus pneumoniae (glycoconjugates) and a saponin-containing liposomal adjuvant. The immunogenic compositions of the present invention generally comprise a glycoconjugate, wherein the saccharide is derived from a serotype of Streptococcus pneumoniae. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against Streptococcus pneumoniae infection using the novel immunogenic compositions. Infections caused by Streptococcus pneumoniae are a leading cause of morbidity and mortality worldwide. Pneumonia, febrile bacteremia, and meningitis are the most common manifestations of invasive pneumococcal infection, while spread of the bacteria within the respiratory tract can lead to middle ear infections, sinusitis, or recurrent bronchitis. Non-invasive manifestations are generally less severe than invasive infections but are significantly more common. In Europe and the United States, pneumococcal pneumonia is the most common community-acquired bacterial pneumonia, affecting an estimated 100 adults per 100,000 annually. The corresponding figures for febrile bacteremia and meningitis are 15 to 19 per 100,000 and 1 to 2 per 100,000, respectively. The risk of one or more of these manifestations is much higher in infants and the elderly, as well as in immunocompromised persons of any age. Even in economically developed areas, invasive pneumococcal infection carries a high mortality rate; the mortality rate for adults with pneumococcal pneumonia averages 10% to 20%, and it may exceed 50% in high-risk groups. Pneumonia is by far the most common cause of death from pneumococcus worldwide. The causative agent of pneumococcal infection, Streptococcus pneumoniae (pneumococcus), is a Gram-positive, encapsulated coccus surrounded by a polysaccharide capsule. Variation in the composition of this capsule allows serological distinction between approximately 91 capsular types, some of which are frequently associated with pneumococcal infection, while others are rarely associated. Invasive pneumococcal infections include pneumonia, meningitis, and febrile bacteremia; common noninvasive manifestations include otitis media, sinusitis, and bronchitis. Pneumococcal conjugate vaccine (PCV) is a pneumococcal vaccine used to protect against diseases caused by Streptococcus pneumoniae (pneumococcus). Currently, there are five PCV vaccines available on the global market: Prevnar ® (called Prevenar in some countries) (seven-valent vaccine), SYNFLORIX ® (decavalent vaccine), Prevnar 13 ®(13-valent vaccine), Vaxneuvance TM (15-valent vaccine) and Prevnar 20 TM (20-valent vaccine). The recent development of microorganisms resistant to essential antibiotics and the increase in the number of immunocompromised people highlight the need for pneumococcal vaccines with even broader protection. Specifically, since it is not found in Prevnar 13 ® Given the potential for serotype shifts over time, there is a need to address the unmet medical need for coverage of pneumococcal infections. ® The pathogenicity specificity of the 13 serotypes of S. pneumoniae varies by region and ethnic group and may change over time due to the acquisition of antibiotic resistance, the introduction of pneumococcal vaccines, and secular trends of unknown origin. There is a need for immunogenic compositions that can be used in humans, and particularly in children under 2 years of age, to induce immune responses against additional S. pneumoniae serotypes. The purpose of the novel immunogenic composition of the present invention is to provide a novel immunogenic composition for the treatment of TM In one aspect, the immunogenic composition of the present invention is intended to provide protection against additional S. pneumoniae serotypes not found in Vaxneuvance TM and / or Prevnar 20 TM The vaccine provides adequate protection against additional S. pneumoniae serotypes found in the wild, while maintaining immune responses against serotypes currently covered by the vaccine. 1. Streptococcus pneumoniae saccharide conjugates of the present invention The present invention relates in part to conjugated Streptococcus pneumoniae capsular saccharide antigens (also referred to as glycoconjugates). For the purposes of the present invention, the term "glycoconjugate" indicates a Streptococcus pneumoniae capsular saccharide that is conjugated to a carrier protein via a covalent or non-covalent bond. In one embodiment, the Streptococcus pneumoniae capsular saccharide is conjugated to a carrier protein via a non-covalent bond (such as the rhizavidin / biotin system, see, for example, WO2012155007, WO2020056202). The capsular saccharide is preferably conjugated via a covalent bond. In one embodiment, the capsular saccharide is directly conjugated to the carrier protein. In a second embodiment, the capsular saccharide is conjugated to the carrier protein via a spacer / linker. 1.1 Streptococcus pneumoniae capsular saccharide of the present invention Throughout this specification, the term "saccharide" may refer to a polysaccharide or an oligosaccharide and includes both. In one embodiment, the saccharide of the present invention may be an oligosaccharide. Oligosaccharides have a small number of repeating units (usually 5 to 15 repeating units) and are generally synthesized or derived by hydrolysis of polysaccharides. However, all saccharides of the present invention and in the immunogenic compositions of the present invention are preferably polysaccharides. High molecular weight polysaccharides are capable of inducing specific antibody immune responses due to the presence of epitopes on the surface of the antigen. It is preferably contemplated that isolated and purified high molecular weight capsular polysaccharides are used in the conjugates, compositions and methods of the present invention. Therefore, in preferred embodiments of the present invention, the saccharide is a polysaccharide. The saccharide used in the present invention is preferably a Streptococcus pneumoniae capsular saccharide (also referred to herein as "Streptococcus pneumoniae capsular saccharide" S. pneumoniae capsular saccharide) or "capsular saccharide"). Capsules are found in several medically important bacteria. Bacterial capsules are primarily composed of polysaccharides. Capsular saccharides are prepared by standard techniques known to those skilled in the art. In one embodiment, the S. pneumoniae capsular saccharide used in the present invention is a synthetic carbohydrate. However, in a preferred embodiment, the source of the S. pneumoniae capsular saccharide according to the present invention can be S. pneumoniae cells. S. pneumoniae strains that can be used as a source of capsular saccharides can be obtained from established culture collections (such as, for example, the American Type Culture Collection (ATCC, Manassas, VA USA) or the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinical samples. Pneumococcal capsular saccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art (see, for example, the methods disclosed in US2006 / 0228380, US2006 / 0228381, US2007 / 0184071, US2007 / 0184072, US2007 / 0231340 and US2008 / 0102498 and WO2008 / 118752). Pneumococcal capsular saccharides can also be produced using synthetic schemes known to those skilled in the art. If the pneumococcal capsular saccharide is obtained directly from the bacteria, the bacterial cells can be grown in a culture medium (e.g., a soy-based culture medium). After fermentation, the bacterial cells can be lysed to produce a cell lysate. The capsular saccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, depth filtration, precipitation, ultrafiltration, treatment with activated carbon, diafiltration, and / or column chromatography (see, e.g., US2006 / 0228380, US2006 / 0228381, and WO2008 / 118752). The purified capsular saccharide can then be used to prepare an immunogenic conjugate. The isolated capsular saccharides obtained by purification can be characterized by various parameters, including, for example, weight average molecular weight (Mw). The molecular weight of the polysaccharide can be measured by size exclusion chromatography (SEC) in combination with a multi-angle laser light scattering detector (MALLS). The capsular saccharide used in the present invention is the capsular saccharide from Streptococcus pneumoniae. The capsular saccharide used in the present invention is preferably a capsular saccharide from the following serotypes of Streptococcus pneumoniae: serotype 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 6E, 6F, 6G, 6H, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9V, 9N, 10A, 10B, 10C, 10F, 11A, 11B, 11C, 11D, 11E, 11F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 16A, 16F, 17A, 17F, 18A, 18 B, 18C, 18F, 19A, 19B, 19C, 19F, 20A, 20B, 21, 22A, 22F, 23A, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31, 32A , 32F, 33A, 33B, 33C, 33D, 33E, 33F, 34, 35A, 35B, 35C, 35F, 36, 37, 38, 39, 40, 41A, 41F, 42, 43, 44, 45, 46, 47A, 47F and 48. Capsular saccharides used in the present invention are preferably capsular saccharides from a serotype of S. pneumoniae selected from serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 7C, 7F, 8, 9V, 9N, 10A, 10B, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20A, 20B, 21, 22A, 22F, 23A, 23B, 23F, 24B, 24F, 27, 29, 31, 33B, 33F, 34, 35B, 35F, 38, 72, and 73. The S. pneumoniae capsular polysaccharide comprises repeating oligosaccharide units that may contain up to 8 sugar residues. In one embodiment, the capsular saccharide of the present invention can be a single oligosaccharide unit, or a shorter sugar chain than the natural length of a repeating oligosaccharide unit. In one embodiment, the capsular saccharide of the present invention is a repeating oligosaccharide unit of the relevant serotype. In one embodiment, the capsular saccharide of the present invention may be an oligosaccharide. Oligosaccharides have a small number of repeating units (usually 5 to 15 repeating units) and are usually synthesized or derived by hydrolysis of polysaccharides. In preferred embodiments, the capsular saccharide of the present invention is a polysaccharide. High-molecular-weight capsular polysaccharides are capable of inducing specific antibody immune responses due to the presence of epitopes on the antigenic surface. Isolated and purified high-molecular-weight capsular polysaccharides are preferably used in the conjugates, compositions, and methods of the present invention. In a preferred embodiment, the isolated capsular saccharide used in the present invention (purified before further processing) has a weight average molecular weight between 50 kDa and 5000 kDa. In a preferred embodiment, the capsular saccharide used in the present invention has a weight average molecular weight between 200 kDa and 4000 kDa. Any integer within any of the above ranges is considered an embodiment of the present disclosure. 1.2 Properties of the S. pneumoniae saccharide conjugates of the present invention In general, conjugation of the saccharide to a carrier enhances the immunogenicity of the saccharide because it converts the saccharide from a T-independent antigen to a T-dependent antigen, thus allowing the initiation of immunological memory. Conjugation is particularly useful for pediatric vaccines. The isolated capsular saccharides described above may be activated (eg, chemically activated) to enable reaction (eg, with a linker or directly with a carrier protein) and then incorporated into a glycoconjugate, as further described herein. Prior to activation, the size of the isolated polysaccharide can be reduced while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used. In one embodiment, the size of the isolated polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis may be performed using a weak acid (e.g., acetic acid, formic acid, propionic acid). In one embodiment, the chemical hydrolysis is performed using formic acid. In one embodiment, the chemical hydrolysis is performed using propionic acid. In a preferred embodiment, the chemical hydrolysis is performed using acetic acid. Chemical hydrolysis may also be performed using a diluted strong acid (such as diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitric acid, or diluted perchloric acid). In one embodiment, the chemical hydrolysis is performed using diluted hydrochloric acid. In one embodiment, the chemical hydrolysis is performed using diluted sulfuric acid. In one embodiment, the chemical hydrolysis is performed using diluted phosphoric acid. In one embodiment, the chemical hydrolysis is performed using diluted nitric acid. In one embodiment, the chemical hydrolysis is performed using diluted perchloric acid. The size of the isolated polysaccharide can also be reduced by mechanical homogenization. In one embodiment, the size of the isolated polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate is increased by using a higher applied homogenization pressure, and the exposure time can be increased by recirculating the feed stream through the homogenizer. The weight average molecular weight (Mw) of the saccharide prior to conjugation refers to the Mw of the saccharide prior to activation (i.e., after the final size fractionation step but before the saccharide is reacted with the activating agent). In the context of the present invention, the Mw of the saccharide is not substantially modified by the activation step, and the Mw of the saccharide incorporated into the conjugate is similar to the Mw of the saccharide measured prior to activation. In one embodiment, the pneumococcal saccharide conjugate of the present invention comprises pneumococcal capsular saccharide, wherein the weight average molecular weight (Mw) of the saccharide before conjugation is between 50 kDa and 1,000 kDa. In one embodiment, the pneumococcal saccharide conjugate of the present invention comprises pneumococcal capsular saccharide, wherein the weight average molecular weight (Mw) of the saccharide before conjugation is between 50 kDa and 600 kDa. In one embodiment, the pneumococcal saccharide conjugate of the present invention comprises pneumococcal capsular saccharide, wherein the weight average molecular weight (Mw) of the saccharide before conjugation is between 50 kDa and 500 kDa. In some embodiments, the S. pneumoniae glycoconjugates of the present invention have a weight average molecular weight (Mw) between 250 kDa and 20,000 kDa. In some embodiments, the S. pneumoniae glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. Another way to characterize the pneumococcal glycoconjugates of the present invention is by the presence of a carrier protein (e.g., CRM) to which the glycoconjugates are attached. 197 The saccharide can be characterized by the extent of bound lysine residues (degree of conjugation) in the carrier protein (e.g., SCP, DT, or TT). Evidence of lysine modification of the carrier protein due to covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Conjugation can result in a reduction in the number of recovered lysine residues compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the degree of conjugation of the S. pneumoniae saccharide conjugates of the present invention is between 2 and 15. The S. pneumoniae saccharide conjugates of the present invention can also be characterized by the saccharide to carrier protein ratio (weight / weight). In some embodiments, the ratio of S. pneumoniae capsular saccharides to carrier protein (w / w) in the saccharide conjugate is between 0.5 and 3.0. In other embodiments, the ratio of saccharides to carrier protein (w / w) is between 0.5 and 2.0. In other embodiments, the ratio of saccharides to carrier protein (w / w) is between 0.5 and 1.5. In other embodiments, the ratio of saccharides to carrier protein (w / w) is between 0.8 and 1.2. In other embodiments, the ratio of saccharides to carrier protein (w / w) is between 0.5 and 1.0. In other embodiments, the ratio of saccharides to carrier protein (w / w) is between 1.0 and 1.5. In other embodiments, the ratio of saccharides to carrier protein (w / w) is between 1.0 and 2.0. In further embodiments, the ratio of sugar to carrier protein (w / w) is between 0.8 and 1.2. The pneumococcal saccharide conjugates and immunogenic compositions of the present invention may contain free saccharides that are not bound to a carrier protein but are still present in the saccharide conjugate composition. The free saccharides may be non-covalently associated with the saccharide conjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or embedded in the saccharide conjugate). In preferred embodiments, each pneumococcal saccharide conjugate of the present invention contains less than about 50% free pneumococcal saccharides compared to the total amount of saccharides. In preferred embodiments, each pneumococcal saccharide conjugate of the present invention contains less than about 25% free pneumococcal saccharides compared to the total amount of saccharides. S. pneumoniae glycoconjugates can also be characterized by their molecular size distribution (K d ) characterization. Size exclusion chromatography medium (CL-4B) can be used to determine the relative molecular size distribution of the conjugate. Size exclusion chromatography (SEC) is used in a gravity-fed column to obtain a molecular size distribution profile of the conjugate. Large molecules excluded from the pores in the medium precipitate faster than small molecules. The column precipitate is collected using a fraction collector. The fraction is tested colorimetrically using the sugar assay. To determine K d The column was calibrated to establish the separation of molecules by complete exclusion (V 0), (K d =0), and the maximum retention of the liquid (V i ), (K d =1). Dispensing to achieve specific sample properties (V e ) and K d The relationship is K d =(V e -V 0) / (V i -V 0). In a preferred embodiment, at least 30% of the pneumococcal glycoconjugates of the present invention have a K value less than or equal to 0.3 in a CL-4B column. d In a preferred embodiment, at least 40% of the glycoconjugates have a K value less than or equal to 0.3 in the CL-4B column. d In a preferred embodiment, between 40% and 80% of the pneumococcal glycoconjugates of the present invention have a K value less than or equal to 0.3 in the CL-4B column. d 1.3 Preparation of the Streptococcus pneumoniae glycoconjugate of the present invention The pneumococcal saccharide conjugates of the present invention can be prepared by any coupling technique known to those skilled in the art. In one embodiment, the S. pneumoniae capsular saccharide is coupled to a carrier protein via a non-covalent bond (see, for example, WO2012155007, WO2020056202). In one embodiment, the capsular saccharide of Streptococcus pneumoniae is covalently bound. In one embodiment, the capsular saccharide is directly bound to the carrier protein. In a second embodiment, the capsular saccharide is bound to the carrier protein via a spacer / linker. In one embodiment, part or all of the pneumococcal saccharide conjugates of the present invention are conjugated to a carrier protein via a linker (e.g., a bifunctional linker). The linker is optionally heterobifunctional or homobifunctional, having, for example, a reactive amine group and a reactive carboxylic acid group, two reactive amine groups, or two reactive carboxylic acid groups. The linker has, for example, between 4 and 20 carbon atoms, 4 and 12 carbon atoms, or 5 and 10 carbon atoms. A possible linker is adipic acid dihydrazide (ADH). Other linkers include B-propionamido (WO 00 / 10599), nitrophenylethylamine (Gever et al. (1979) Med. Microbiol. Immunol. 165; 171-288), haloalkyl halides (US 4057685), glycosidic linkages (US 4673574, US 4808700), hexamethylenediamine, and 6-aminohexanoic acid (US 4459286). In one embodiment, part or all of the Streptococcus pneumoniae saccharide conjugates of the present invention are directly conjugated to a carrier protein (without a linker). In general, the following types of chemical groups on protein carriers can be used for coupling / conjugation: 1) Amine (e.g., via lysine). In one embodiment, this group is linked directly to a carboxyl group on the saccharide or to a carboxyl group on a linker using carbodiimide chemistry, such as with EDAC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). In another embodiment, this group is linked directly to a hydroxyl group on the saccharide activated with CDAP or CNBr, or to such groups on a linker; to a saccharide or to a linker with an aldehyde group; or to a saccharide or to a linker with a succinimidyl group. 2) Carboxyl (e.g., via aspartic acid or glutamate). In one embodiment, this group is linked directly to an amine group on the saccharide or to an amine group on a linker using carbodiimide chemistry, such as with EDAC. 3) Sulfhydryl (e.g., via cysteine). In one embodiment, this group is linked to a bromo- or chloroacetylated sugar or to a linker using maleimide chemistry. In one embodiment, this group is activated / modified with bis(nitrogen benzidine). 4) Hydroxyl (e.g., via tyrosine). In one embodiment, this group is activated / modified with bis(nitrogen benzidine). 5) Imidazolyl (e.g., via histidine). In one embodiment, this group is activated / modified with bis(nitrogen benzidine). 6) Guanidino (e.g., via arginine). 7) Indolyl (e.g., via tryptophan). On the S. pneumoniae saccharide, the following groups are usually available for coupling: OH, COOH or NH2. Aldehyde groups can be generated after different treatments known in the art, such as: periodate, acid hydrolysis, hydrogen peroxide, etc. In one embodiment, some or all of the pneumococcal saccharide conjugates of the present invention are prepared using CDAP chemistry. In this embodiment, pneumococcal saccharides are activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form cyanate esters. The activated saccharides can then be coupled to amine groups on a carrier protein, either directly or via a spacer (linker) group. For example, the spacer may be cystamine or cysteamine, which gives a thiolated polysaccharide that can be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl)aminobenzoate (S1AB), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfoSIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino]propionate (SBAP)). In a preferred embodiment, the activated sugar cyanate is coupled with hexamethylenediamine or adipic acid dihydrazide (ADH) and the amine-derivatized sugar is conjugated to the carrier protein via the carboxyl groups on the protein carrier using carbodiimide chemistry (e.g., EDAC or EDC). Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. In one embodiment, some or all of the pneumococcal saccharide conjugates of the present invention are prepared using carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, or TSTU. Many of these techniques are described in International Patent Application Publication No. WO 98 / 42721. Conjugation can involve a carbonyl linker, which can be formed by reacting a free hydroxyl group of the saccharide with CDI (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with the protein to form a carbamate linkage. This can involve reducing the mutarotomer terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amine group on the protein. Direct reductive amination In one embodiment, part or all of the Streptococcus pneumoniae saccharide conjugates of the present invention are prepared by direct reductive amination (see, for example, US 4365170, US 4673574, WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of purified S. pneumoniae saccharides, and (2) reduction of the activated saccharides and a carrier protein (e.g., CRM 197 , TT or SCP) to form glycoconjugates. As described above, size fractionation of the S. pneumoniae saccharides to a target molecular weight (MW) range can be performed prior to oxidation. Thus, in one embodiment, the isolated polysaccharides are size fractionated prior to oxidation. In one embodiment, the pneumococcal saccharide of the present invention is conjugated to a carrier protein by a process comprising the following steps: (a) reacting the pneumococcal saccharide with an oxidizing agent; (b) compounding the activated saccharide of step (a) with a carrier protein; and (c) reacting the complexed activated saccharide and carrier protein with a reducing agent to form a glycoconjugate. In one embodiment, the pneumococcal saccharide of the present invention is conjugated to a carrier protein by a process comprising the following steps: (a) reacting the pneumococcal saccharide with an oxidizing agent; (a') quenching the oxidation reaction by adding a quenching agent; (b) complexing the activated saccharide from step (a') with a carrier protein; and (c) reacting the complexed activated saccharide and carrier protein with a reducing agent to form a glycoconjugate. After the oxidation step (a), the sugars are considered activated and are referred to as "activated sugars." In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4 - ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In one embodiment, the oxidizing agent is periodate in the presence of a divalent cation (see WO 2008 / 143709). In one embodiment, the oxidant is periodic acid. In one embodiment, the oxidant is periodic acid in the presence of divalent cations. In one embodiment, the oxidant is periodic acid in the presence of Mg 2+ In one embodiment, the oxidant is periodic acid in the presence of Ca 2+ In one embodiment, the oxidizing agent is orthoperiodate. In a preferred embodiment, the oxidant is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In one embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.01 to 2 molar equivalents of periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.1 to 1.0 molar equivalents of periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.1 to 0.5 molar equivalents of periodate. In one embodiment, the oxidizing agent is a mixture of a stable nitroxyl compound and an oxidizing agent (see WO2014097099). In one aspect, the stable nitroxyl compound is a molecule bearing a TEMPO or PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably, the molecule selectively oxidizes a primary alcohol in the presence of an oxidizing agent to produce an aldehyde group without affecting secondary hydroxyl groups. More preferably, the molecule selectively oxidizes a primary alcohol in the presence of an oxidizing agent to produce an aldehyde group without excessive oxidation to a carboxyl group. In one embodiment, the stable nitro compound is TEMPO, 2,2,6,6-tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-phosphonyloxy-TEMPO, 4-oxo-TEMPO, 4-methoxy-TEMPO, 4-isothiocyanato-TEMPO, 4-(2-iodoacetamido)-TEMPO free base, 4-hydroxy-TEMPO, 4-cyano-TEMPO, 4-carboxyl-TEMPO, 4-(2-bromoacetamido)-TEMPO, 4-amino-TEMPO, or 4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxide. The stable nitro compound is preferably TEMPO. In one embodiment, the stable nitro compound is selected from the group consisting of TEMPO, 2,2,6,6-tetramethyl-4-(methylsulfonyloxy)-1-piperidinyl oxide, 4-phosphonyloxy-TEMPO, 4-oxo-TEMPO, 4-methoxy-TEMPO, 4-isothiocyanato-TEMPO, 4-(2-iodoacetamido)-TEMPO free base, 4-hydroxy-TEMPO, 4-cyano-TEMPO, 4-carboxyl-TEMPO, 4-(2-bromoacetamido)-TEMPO, 4-amino-TEMPO, and 4-acetamido-2,2,6,6-tetramethylpiperidinyl 1-oxide. The stable nitro compound is preferably TEMPO. In a further aspect, the stable nitroxyl compound is 3β-DOXYL-5α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, 5-DOXYL-stearate methyl ester, 3-(aminomethyl)-PROXYL, 3-aminoformyl-PROXYL, 3-aminoformyl-2,2,5,5-tetramethyl-3-pyrroline 1-oxide, 3-carboxy-PROXYL, or 3-cyano-PROXYL. In a further aspect, the stable nitroxyl compound is selected from the group consisting of 3β-DOXYL-5α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, 5-DOXYL-stearate methyl ester, 3-(aminomethyl)-PROXYL, 3-aminoformyl-PROXYL, 3-aminoformyl-2,2,5,5-tetramethyl-3-pyrroline 1-oxide, 3-carboxy-PROXYL, and 3-cyano-PROXYL. In one embodiment, the oxidizing agent is a molecule bearing an N-halogen moiety. Preferably, the molecule has the ability to selectively oxidize a primary alcohol in the presence of a nitro compound. In one embodiment, the oxidizing agent is N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, diiodoisocyanuric acid, or 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In one embodiment, the oxidizing agent is selected from the group consisting of N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-trioxane-2,4,6-trione, dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-trioxane-2,4,6-trione, diiodoisocyanuric acid, and 1,3,5-triiodo-1,3,5-trioxane-2,4,6-trione. Preferably, the oxidizing agent is N-chlorosuccinimide. In one embodiment, the stable nitro compound is 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) and the oxidizing agent is N-chlorosuccinimide (NCS). In one embodiment, the quencher in step a′) is selected from vicinal diols, 1,2-amino alcohols, amino acids, glutathione, sulfites, bisulfates, dithionites, metabisulfites, thiosulfates, phosphites, hypophosphites, or phosphorous acid. In one embodiment, the quencher is a 1,2-amino alcohol of formula (I): where R 1 is selected from H, methyl, ethyl, propyl or isopropyl. In one embodiment, the quencher is selected from sodium and potassium salts of sulfites, bisulfates, dithiosulfinates, metabisulfites, thiosulfates, phosphites, hypophosphites, or phosphorous acids. In one embodiment, the quencher is an amino acid. In these embodiments, the amino acid can be selected from serine, threonine, cysteine, cystine, methionine, proline, hydroxyproline, tryptophan, tyrosine, and histidine. In one embodiment, the quencher is a sulfite, such as bisulfate, dithiosulfinate, metabisulfite, or thiosulfate. In one embodiment, the quencher is a compound comprising two vicinal hydroxyl groups (vicinal diol), ie, the two hydroxyl groups are covalently linked to two adjacent carbon atoms. The quencher is preferably a compound of formula (II): where R 1 and R 2 Each is independently selected from H, methyl, ethyl, propyl or isopropyl. In a preferred embodiment, the quencher is glycerol, ethylene glycol, 1,2-propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, or ascorbic acid. In an even more preferred embodiment, the quencher is 2,3-butylene glycol. In a preferred embodiment, the degree of oxidation of the activated pneumococcal saccharide (also referred to as "activation degree" in this document) is between 2 and 30. In one embodiment, the degree of oxidation (DO) of the activated pneumococcal saccharide is between 10 and 25. In one embodiment, the activated saccharide and carrier protein are lyophilized prior to step b). In one embodiment, the initial input ratio (weight ratio) of activated pneumococcal saccharide to carrier protein in step b) is between 4:1 and 0.1:1. In one embodiment, the initial input ratio (weight ratio) of activated pneumococcal saccharide to carrier protein in step b) is between 1.5:1 and 0.5:1. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. In another embodiment, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulfoxide (DMSO) or dimethylformamide (DMF). In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylformamide (DMF). In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in a solution consisting essentially of dimethylsulfoxide (DMSO) or dimethylformamide (DMF). In one embodiment, the reduction reaction (c) is carried out in a solution consisting essentially of dimethylformamide (DMF). In one embodiment, the reduction reaction (c) is carried out in a solution consisting essentially of dimethylsulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) or DMF (dimethylformamide) solvent. In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Brønsted acid or a Lewis acid, an amine borane such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMe i PrN-BH 3. Benzylamine-BH 3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In one embodiment, between 0.2 and 20 molar equivalents of reducing agent are used in step c). In one embodiment, between 0.5 and 10 molar equivalents of reducing agent are used in step c). In one embodiment, between 1.0 and 5 molar equivalents of reducing agent are used in step c). At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH 4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 10 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 5 molar equivalents of sodium borohydride. CDI and / or CDT Chemical In one embodiment, part or all of the S. pneumoniae saccharide conjugates of the present invention are prepared by CDI and / or CDT chemistry, as disclosed in WO2022249107. CDI and / or CDT chemistry involves two steps: (1) reacting S. pneumoniae saccharides with CDI and / or CDT in an aprotic solvent to produce activated saccharides (activation), and (2) reacting the activated saccharides with a carrier protein (e.g., CRM). 197 , TT or SCP) to form a glycoconjugate. In one embodiment, the activating agent in step (1) is 1,1'-carbonyldiimidazole (CDI). In one embodiment, the activating agent in step (1) is 1,1'-carbonyl-di-(1,2,4-triazole) (CDT). As described above, size fractionation of S. pneumoniae saccharides to a target molecular weight (MW) range can be performed prior to activation with CDI and / or CDT. Thus, in one embodiment, the S. pneumoniae saccharides are size-fractionated prior to activation with CDI. In one embodiment, the isolated polysaccharides are size-fractionated prior to activation with CDT. In one embodiment, the S. pneumoniae saccharides are size-fractionated to any of the target molecular weight (MW) ranges defined above. Therefore, in one embodiment, the pneumococcal saccharide is conjugated to a carrier protein by a process comprising the following steps: (a) reacting the isolated polysaccharide with CDI and / or CDT in an aprotic solvent; (b) reacting the activated polysaccharide of step (a) with a carrier protein in an aprotic solvent to form a glycoconjugate. After step (a), the polysaccharide is considered activated and is referred to as "activated polysaccharide". In one embodiment, step a) comprises reacting a S. pneumoniae saccharide with CDI. In one embodiment, step a) comprises reacting the pneumococcal saccharide with an amount of CDI that is between 0.5 and 10 molar equivalents relative to the amount of pneumococcal saccharide present in the reaction mixture. In one embodiment, step a) comprises reacting the S. pneumoniae saccharide with CDT. In one embodiment, step a) comprises reacting the pneumococcal saccharide with an amount of CDT that is between 0.5 and 10 molar equivalents of the amount of pneumococcal saccharide present in the reaction mixture. In one embodiment, the activation reaction a) is carried out in the presence of dimethylsulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2-pyrrolidone, or hexamethylphosphatide (HMPA). In one embodiment, the activation reaction a) is carried out in the presence of dimethylsulfoxide (DMSO). In one embodiment, the activation reaction a) is carried out in a solution consisting essentially of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). In one embodiment, the activation reaction a) is carried out in a solution consisting essentially of dimethyl sulfoxide (DMSO). In one embodiment, the coupling reaction b) is carried out in the presence of dimethylsulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2-pyrrolidone or hexamethylphosphatide (HMPA). In one embodiment, the coupling reaction b) is performed in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the coupling reaction b) is carried out in a solution consisting essentially of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). In one embodiment, the coupling reaction b) is carried out in a solution consisting essentially of dimethyl sulfoxide (DMSO). In one embodiment, the weak organic base can be added to the reaction mixture after the activation reaction a) but before the conjugation reaction b). The weak organic base can be added before or after the carrier protein is introduced into the reaction mixture. Thus, in one embodiment, the weak organic base is added to the reaction mixture before the carrier protein is introduced. In another embodiment, the weak organic base is added to the reaction mixture after the carrier protein is introduced. The weak organic base can be selected from alkaneamines, imidazoles, triazoles, pyridines, histidine, and guanidines. Alkaneamines include alkyl primary amines such as methylamine, ethylamine, propylamine, and isopropylamine; alkyl secondary amines such as dimethylamine, diethylamine, dipropylamine, and diisopropylamine; and alkyl tertiary amines such as trimethylamine, triethylamine, triisopropylamine, and di-N,N'-isopropylethylamine. In one embodiment, the weak organic base is an alkaneamine. In one embodiment, the weak organic base is imidazole. In one embodiment, the weak organic base is triazole. In one embodiment, the weak organic base is pyridine. In one embodiment, the weak organic base is histidine. In one embodiment, the weak organic base is guanidine. In one embodiment, after the binding reaction b), the unbound reaction sites of the activated polysaccharide are hydrolyzed. In one embodiment, the unbound reaction sites are hydrolyzed by adding to a binding solution of an aqueous solution. In one embodiment, the unbound reaction sites are hydrolyzed by adding to a binding solution of an aqueous buffer solution. In one embodiment, the unbound reaction sites are hydrolyzed by adding to a binding solution of an aqueous buffer solution and adjusting the pH to between about 3.0 and about 10.0. In one embodiment, the unbound reaction sites are hydrolyzed by adding to a binding solution of an aqueous buffer solution and adjusting the pH to between about 7.0 and about 10.0. In one embodiment, the unbound reaction sites are hydrolyzed by adding to a binding solution of an aqueous buffer solution and adjusting the pH to between about 3.0 and about 7.0. In one embodiment, the unbound reaction sites are hydrolyzed by adding to a binding solution of an aqueous buffer solution and adjusting the pH to between about 4.0. In one embodiment, unbound reactive sites are hydrolyzed by adding to a binding solution in an aqueous buffer solution and adjusting the pH to about 9.0. eTEC Chemistry In one embodiment, part or all of the Streptococcus pneumoniae glycoconjugates of the present invention are prepared by eTEC chemistry, as disclosed in WO2014027302. The eTEC spacer comprises seven linear atoms (i.e., -C(O)NH(CH2)2SCH2C(O)-) and provides stable thioether and amide bonds between the sugar and the carrier protein. Synthesis of eTEC-linked glycoconjugates involves the reaction of activated hydroxyl groups of the sugar with an amine group of a sulfanylamine reagent (e.g., cystamine or cysteine amine or a salt thereof) to form a carbamate linkage to the sugar to provide a thiolated sugar. Generation of one or more free sulfhydryl groups is accomplished by reaction with a reducing agent to provide an activated thiolated sugar. Reaction of the free sulfhydryl groups of the activated thiolated sugar with an activated carrier protein having one or more α-haloacetamide groups on an amine-containing residue generates a thioether bond for conjugate formation, wherein the carrier protein is linked to the eTEC spacer via an amide bond. Therefore, in one embodiment, the pneumococcal saccharide conjugate of the present invention comprises a pneumococcal saccharide covalently bound to a carrier protein via an eTEC spacer. In one embodiment, part or all of the Streptococcus pneumoniae saccharide conjugates of the invention comprise a Streptococcus pneumoniae saccharide conjugated to a carrier protein via a 2-((2-oxoethyl)thio)ethyl) carbamate (eTEC) spacer, wherein the saccharide is covalently linked to the eTEC spacer via a carbamate linkage, and wherein the carrier protein is covalently linked to the eTEC spacer via an amide linkage. The eTEC-linked glycoconjugate of the present invention can be represented by the general formula (III): , where (sugar) represents the pneumococcal sugar. Formula (III) is a schematic representation of the glycoconjugates of the present invention. It should not be understood that there is only one linkage between the saccharide and the carrier protein. Instead, each carrier protein molecule can be linked to more than one pneumococcal saccharide molecule and each saccharide molecule can be linked to more than one carrier protein molecule. In addition, the majority of the saccharide repeat units remain unmodified, and the covalent bond between the carrier protein and the saccharide is limited to a minority of the saccharide repeat units. Click Chemistry In one embodiment, part or all of the Streptococcus pneumoniae saccharide conjugates of the present invention are prepared by click chemistry (see, for example, PCT / IB2023 / 050202). Therefore, in one embodiment, part or all of the pneumococcal saccharide conjugates of the present invention comprise pneumococcal saccharides covalently bound to a carrier protein (CP) via a spacer and having the general formula (IV): , wherein X is selected from the group consisting of: CH 2(CH 2) n’ 、(CH 2CH 2O) m CH 2CH 2. NHCO(CH 2) n’ 、NHCO(CH 2CH 2O) m CH 2CH 2. OCH 2(CH 2) n’ and O(CH 2CH 2O) m CH 2CH 2; wherein n' is selected from 1 to 10 and m is selected from 1 to 4, wherein X' is selected from the group consisting of: CH 2O(CH 2) n’’ CH 2C=O, CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4, wherein the structure in square brackets represents a repeating unit of the Streptococcus pneumoniae saccharide, and wherein n represents the number of repeating units. In a particular aspect, the present invention is directed to a pneumococcal saccharide conjugate comprising a pneumococcal saccharide covalently bound to a carrier protein (CP) via a spacer and having the general formula (IV), wherein X is CH 2(CH 2) n’ , wherein n' is 2, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, where n'' is 1. In a particular aspect, the present invention relates to a S. pneumoniae saccharide conjugate comprising a S. pneumoniae saccharide of formula (V) covalently bound to a carrier protein (CP) via a spacer, where the structure in square brackets represents the repeating unit of the S. pneumoniae saccharide, and where n represents the number of repeating units. In one aspect, part or all of the pneumococcal saccharide conjugates of the present invention comprise pneumococcal saccharides covalently bound to a carrier protein (CP) via a spacer and having the general formula (VI): , wherein X is selected from the group consisting of: CH 2(CH 2) n’ 、(CH 2CH 2O) m CH 2CH 2. NHCO(CH 2) n’ 、NHCO(CH 2CH 2O) m CH 2CH 2. OCH 2(CH 2) n’ and O(CH 2CH 2O) m CH 2CH 2; wherein n' is selected from 0 to 10 and m is selected from 1 to 4, wherein X' is selected from the group consisting of: CH 2(CH 2) n” 、CH 2O(CH 2) n’’ CH 2. CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4, and wherein the structure in square brackets represents a repeating unit of the Streptococcus pneumoniae saccharide, and wherein n represents the number of repeating units. In a particular aspect, the present invention is directed to a pneumococcal saccharide conjugate comprising a pneumococcal saccharide covalently bound to a carrier protein (CP) via a spacer and having the general formula (VI), wherein X is CH 2(CH 2) n’ , wherein n' is 0, and wherein X' is CH 2(CH 2) n” , where n'' is 0. In a particular aspect, the present invention relates to a Streptococcus pneumoniae saccharide conjugate comprising a Streptococcus pneumoniae saccharide of formula (VII) covalently bound to a carrier protein (CP) via a spacer, where the structure in square brackets represents the repeating unit of the S. pneumoniae saccharide, and where n represents the number of repeating units. Formulas (IV), (V), (VII), and (VII) are schematic representations of glycoconjugates of the present invention. It should not be understood that linkages exist on every repeating unit of the saccharide (structures in square brackets). Instead, the majority of the saccharide repeating units remain unmodified, and the covalent linkages between the carrier protein and the saccharide are limited to a minority of the saccharide repeating units. Furthermore, individual carrier protein (CP) molecules may be linked to more than one saccharide molecule, and individual saccharide molecules may be linked to more than one individual carrier protein (CP) molecule. The structures in square brackets represent the repeating units of the Streptococcus pneumoniae saccharide. After being bound to the carrier protein, the pneumococcal glycoconjugates of the present invention can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. Such techniques include dialysis, concentration / diafiltration operations, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography) and depth filtration. Thus, in one embodiment, the process for producing the pneumococcal glycoconjugates of the present invention includes a step of purifying the pneumococcal glycoconjugates after production. 1.4 Pneumococcal serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F glycoconjugates of the present invention In one aspect, the invention relates to a composition comprising a glycoconjugate of S. pneumoniae serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F. The structures of S. pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F polysaccharides are known in the art (see, e.g., Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899). In one embodiment, the pneumococcal serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular saccharides used in the present invention are synthetic carbohydrates. The preparation of synthetic pneumococcal type 1 capsular saccharides can be carried out, for example, as disclosed in WO2015004041. The preparation of synthetic pneumococcal type 4 capsular saccharides can be carried out, for example, as disclosed in WO2016091399. The preparation of synthetic pneumococcal type 5 capsular saccharides can be carried out, for example, as disclosed in WO2016198170. The preparation of synthetic pneumococcal type 8 capsular saccharides can be carried out, for example, as disclosed in WO2017220753. However, in a preferred embodiment, the source of the bacterial polysaccharide according to the present invention can be Streptococcus pneumoniae bacterial cells. Bacterial strains that can be used as a source of Streptococcus pneumoniae capsular polysaccharides can be obtained from established culture collections (such as, for example, from the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinical samples. S. pneumoniae serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharides can be obtained directly from the bacteria using isolation procedures known to those of ordinary skill in the art. These are also commercially available, such as, for example, from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., Reference Nos. ATCC 13-X, ATCC 36-X, ATCC 41-X, ATCC 280-X, ATCC 107-X, ATCC 284-X, ATCC 505-X, ATCC 331-X, ATCC 511-X, ATCC 514-X, ATCC 517-X, ATCC 520-X, ATCC 81-X, ATCC 289-X, ATCC 304-X, ATCC 101-X, ATCC 527-X, ATCC 104-X, ATCC 535-X). If the capsular polysaccharide system is directly obtained from bacteria, the bacterial cells can be grown in a culture medium (preferably in a soybean-based culture medium). After the bacterial cells producing the pneumococcal capsular polysaccharide are fermented, the bacterial cells can be dissolved to produce cell lysates. The capsular polysaccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, diafiltration and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified capsular polysaccharide can then be used to prepare glycoconjugates. Isolated capsular saccharides can be characterized by various parameters including, for example, weight average molecular weight (Mw). The molecular weight of capsular saccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In preferred embodiments, the isolated capsular polysaccharide (i.e., purified prior to further processing) has a weight average molecular weight between 5 kDa and 5,000 kDa. In one embodiment, the isolated capsular polysaccharide has a weight average molecular weight between 10 kDa and 3,000 kDa. In one embodiment, the isolated capsular polysaccharide has a weight average molecular weight between 50 kDa and 1,000 kDa. Any integer within any of the above ranges is contemplated as an embodiment of the present disclosure. To produce conjugates with favorable filterability characteristics, immunogenicity, and / or yield, the capsular polysaccharide may be size-fractionated to a target molecular weight range prior to conjugation to the carrier protein. It is desirable to reduce the size of purified serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F capsular polysaccharides while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used (see, for example, WO2006 / 110381, WO2015110941). In one embodiment, the size of the purified capsular polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis may be performed using a weak acid (e.g., acetic acid, formic acid, propionic acid). Chemical hydrolysis may also be performed using a diluted strong acid (e.g., diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitric acid, or diluted perchloric acid). The size of the purified polysaccharide can also be reduced by mechanical homogenization. In one embodiment, the size of the purified polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate is increased by using a higher applied homogenization pressure, and the exposure time can be increased by recirculating the feed stream through the homogenizer. In one embodiment, the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide is not size fractionated. The isolated serotype 1 capsular polysaccharide can be de-O-acetylated (see, for example, WO 2008 / 079653). Therefore, in one embodiment, the isolated serotype 1 capsular polysaccharide is partially de-O-acetylated. In one embodiment, the de-O-acetylation is performed using a weak base. Partial de-O-acetylation can be performed using a sodium bicarbonate / sodium carbonate buffer. In one embodiment, the isolated serotype 1 capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa prior to conjugation. In another embodiment, the isolated serotype 1 capsular polysaccharide has a weight average molecular weight of between 150 kDa and 900 kDa prior to conjugation. In a preferred embodiment, the isolated serotype 1 capsular polysaccharide has a weight average molecular weight of between 150 kDa and 700 kDa prior to conjugation. The weight average molecular weight (Mw) of the isolated saccharide prior to conjugation refers to the Mw of the polysaccharide prior to activation (i.e., after the final size fractionation step but before the polysaccharide is reacted with the activating agent). In one embodiment, the isolated serotype 4 capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 4 capsular polysaccharide has a weight average molecular weight of between 300 kDa and 900 kDa before conjugation. In one embodiment, the isolated serotype 5 capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1,000 kDa before conjugation. In one embodiment, the isolated serotype 5 capsular polysaccharide has a weight average molecular weight of between 200 kDa and 600 kDa before conjugation. In one embodiment, the isolated serotype 6A capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 6A capsular polysaccharide has a weight average molecular weight of between 300 kDa and 900 kDa before conjugation. In one embodiment, the isolated serotype 6B capsular polysaccharide has a weight average molecular weight between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 6B capsular polysaccharide has a weight average molecular weight between 200 kDa and 900 kDa before conjugation. In one embodiment, the isolated serotype 7F capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 7F capsular polysaccharide has a weight average molecular weight of between 200 kDa and 900 kDa before conjugation. In one embodiment, the isolated serotype 8 capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 8 capsular polysaccharide has a weight average molecular weight of between 200 kDa and 400 kDa before conjugation. In one embodiment, the isolated serotype 9V capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 9V capsular polysaccharide has a weight average molecular weight of between 200 kDa and 900 kDa before conjugation. In one embodiment, the isolated serotype 10A capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 10A capsular polysaccharide has a weight average molecular weight of between 200 kDa and 900 kDa before conjugation. In one embodiment, the isolated serotype 11A capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 11A capsular polysaccharide has a weight average molecular weight of between 100 kDa and 400 kDa before conjugation. In one embodiment, the isolated serotype 12F capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 12F capsular polysaccharide has a weight average molecular weight of between 150 kDa and 400 kDa before conjugation. In one embodiment, the isolated serotype 14 capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 14 capsular polysaccharide has a weight average molecular weight of between 200 kDa and 900 kDa before conjugation. In one embodiment, the isolated serotype 15B capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 15B capsular polysaccharide has a weight average molecular weight of between 150 kDa and 300 kDa before conjugation. In one embodiment, the isolated serotype 18C capsular polysaccharide has a weight average molecular weight of between 20 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 18C capsular polysaccharide has a weight average molecular weight of between 20 kDa and 500 kDa before conjugation. In one embodiment, the isolated serotype 19A capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 19A capsular polysaccharide has a weight average molecular weight of between 250 kDa and 700 kDa before conjugation. In one embodiment, the isolated serotype 19F capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 19F capsular polysaccharide has a weight average molecular weight of between 250 kDa and 800 kDa before conjugation. In one embodiment, the isolated serotype 22F capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 22F capsular polysaccharide has a weight average molecular weight of between 400 kDa and 700 kDa before conjugation. In one embodiment, the isolated serotype 23F capsular polysaccharide has a weight average molecular weight of between 100 kDa and 1000 kDa before conjugation. In one embodiment, the isolated serotype 23F capsular polysaccharide has a weight average molecular weight of between 200 kDa and 800 kDa before conjugation. In one embodiment, the isolated serotype 33F capsular polysaccharide has a weight average molecular weight of between 300 kDa and 2000 kDa before conjugation. In one embodiment, the isolated serotype 33F capsular polysaccharide has a weight average molecular weight of between 500 kDa and 2000 kDa before conjugation. In one embodiment, the serotype 1 saccharide conjugates of the present invention comprise serotype 1 capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 750 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 250 kDa and 600 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 4 saccharide conjugates of the present invention comprise serotype 4 capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 400 kDa and 900 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 5 saccharide conjugates of the present invention comprise serotype 5 capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 100 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 150 kDa and 800 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 500 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 6A saccharide conjugates of the present invention comprise serotype 6A capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In one embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 300 kDa and 800 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 6B saccharide conjugates of the present invention comprise serotype 6B capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 300 kDa and 800 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 7F saccharide conjugates of the present invention comprise serotype 7F capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 300 kDa and 800 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 8 saccharide conjugates of the present invention comprise serotype 8 capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In one embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 800 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 300 kDa and 600 kDa. In a most preferred embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 400 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 9V saccharide conjugates of the present invention comprise serotype 9V capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In one embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 900 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 300 kDa and 600 kDa. In a most preferred embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 400 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 10A saccharide conjugates of the present invention comprise serotype 10A capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In one embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 800 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 300 kDa and 600 kDa. In a most preferred embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 400 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 11A saccharide conjugates of the present invention comprise serotype 11A capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 75 kDa and 600 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 400 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 12F saccharide conjugates of the present invention comprise serotype 12F capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 100 kDa and 1,000 kDa. In one embodiment, the weight-average molecular weight (Mw) is between 150 kDa and 600 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 150 kDa and 400 kDa. In a most preferred embodiment, the weight-average molecular weight (Mw) is between 250 kDa and 350 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 14 saccharide conjugates of the present invention comprise serotype 14 capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 800 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 600 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 15B saccharide conjugates of the present invention comprise serotype 15B capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 600 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 150 kDa and 300 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 18C saccharide conjugates of the present invention comprise serotype 18C capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 20 kDa and 800 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 20 kDa and 400 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 20 kDa and 200 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 19A saccharide conjugates of the present invention comprise serotype 19A capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In one embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 700 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 250 kDa and 500 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 19F saccharide conjugates of the present invention comprise serotype 19F capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 900 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 250 kDa and 600 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 22F saccharide conjugates of the present invention comprise serotype 22F capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 900 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 400 kDa and 700 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 23F saccharide conjugates of the present invention comprise serotype 23F capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 1,000 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 900 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 200 kDa and 600 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In one embodiment, the serotype 33F saccharide conjugates of the present invention comprise serotype 33F capsular polysaccharide, wherein the weight-average molecular weight (Mw) of the polysaccharide prior to conjugation is between 50 kDa and 2,500 kDa. In another embodiment, the weight-average molecular weight (Mw) is between 100 kDa and 2,000 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 600 kDa and 2,000 kDa. The weight-average molecular weight (Mw) prior to conjugation refers to the Mw of the polysaccharide after activation (i.e., after the final size fractionation step and after reaction of the polysaccharide with the activating agent). In some embodiments, the serotype 1 glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 1 glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 1 glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some embodiments, the serotype 4 glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 4 glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 4 glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some embodiments, the serotype 5 glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 5 glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 5 glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some embodiments, the serotype 6A glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 6A glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 6A glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some embodiments, the serotype 6B glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 6B glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 6B glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some embodiments, the serotype 7F glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 7F glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 7F glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some embodiments, the serotype 8 glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 8 glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 8 glycoconjugates have a weight average molecular weight (Mw) between 2,500 kDa and 8,000 kDa. In some embodiments, the serotype 9V glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 9V glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 9V glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some embodiments, the serotype 10A glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 10A glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 10A glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some embodiments, the serotype 11A glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 11A glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 11A glycoconjugates have a weight average molecular weight (Mw) between 700 kDa and 4,500 kDa. In some embodiments, the serotype 12F glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 12F glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 12F glycoconjugates have a weight average molecular weight (Mw) between 1,500 kDa and 4,000 kDa. In some embodiments, the serotype 14 glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 14 glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 14 glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some embodiments, the serotype 15B glycoconjugates of the present invention have a weight average molecular weight (Mw) between 1,000 kDa and 25,000 kDa. In other embodiments, the serotype 15B glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 20,000 kDa. In preferred embodiments, the serotype 15B glycoconjugates have a weight average molecular weight (Mw) between 5,000 kDa and 15,000 kDa. In some embodiments, the serotype 18C glycoconjugates of the present invention have a weight average molecular weight (Mw) between 150 kDa and 15,000 kDa. In other embodiments, the serotype 18C glycoconjugates have a weight average molecular weight (Mw) between 250 kDa and 7,000 kDa. In preferred embodiments, the serotype 18C glycoconjugates have a weight average molecular weight (Mw) between 300 kDa and 4,000 kDa. In some embodiments, the serotype 19A glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 19A glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred embodiments, the serotype 19A glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 7,500 kDa. In some embodiments, the serotype 19F glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 19F glycoconjugates have a weight average molecular weight (Mw) between 750 kDa and 10,000 kDa. In preferred embodiments, the serotype 19F glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 7,500 kDa. In some embodiments, the serotype 22F glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 10,000 kDa. In other embodiments, the serotype 22F glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 7,500 kDa. In preferred embodiments, the serotype 22F glycoconjugates have a weight average molecular weight (Mw) between 2,500 kDa and 5,500 kDa. In some embodiments, the serotype 23F glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 23F glycoconjugates have a weight average molecular weight (Mw) between 750 kDa and 10,000 kDa. In preferred embodiments, the serotype 23F glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 7,500 kDa. In some embodiments, the serotype 33F glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In other embodiments, the serotype 33F glycoconjugates have a weight average molecular weight (Mw) between 750 kDa and 10,000 kDa. In preferred embodiments, the serotype 33F glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 6,000 kDa. The glycoconjugates of the present invention can also be characterized by the ratio of sugar to carrier protein (weight / weight). In some embodiments, the ratio of serotype 1 polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.6 and 2.0. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 4 polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.9 and 2.1. Even more preferably, the ratio of saccharide to carrier protein (w / w) is between 1.0 and 1.9. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 5 polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 1.3 and 2.5. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 6A polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.7 and 1.6. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 6B polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.4 and 0.8. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 7F polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.7 and 1.5. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 8 polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.6 and 1.6. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 9V polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 1.2 and 2.3. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 10A polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.7 and 1.6. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 11A polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.9 and 1.5. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 12F polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.7 and 1.5. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 14 polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 1.4 and 2.6. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 15B polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.6 and 1.6. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 18C polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.7 and 1.5. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 19A polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.4 and 0.9. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 19F polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.5 and 1.0. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 22F polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.8 and 1.2. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 23F polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 0.4 and 1.0. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . In some embodiments, the ratio of serotype 33F polysaccharide to carrier protein (w / w) in the glycoconjugate is between 0.4 and 3.0. The ratio of saccharide to carrier protein (w / w) is preferably between 1.0 and 2.2. In some of these embodiments, the carrier protein is TT. The carrier protein is preferably CRM. 197 . Another way to characterize the glycoconjugates of the present invention is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) to which the saccharide is bound. The saccharide can be characterized by the extent of bound lysine (the extent of binding). Evidence of lysine modification of the carrier protein due to the covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Conjugation results in a reduction in the number of recovered lysine residues compared to the carrier protein starting material used to generate the conjugate material. In a preferred embodiment, the degree of conjugation of the serotype 1 glycoconjugates of the present invention is between 2 and 15. In a preferred embodiment, the degree of conjugation of the serotype 4 glycoconjugates of the present invention is between 2 and 15. In a preferred embodiment, the degree of conjugation of the serotype 5 glycoconjugates of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 6A glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 6B glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 7F glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the degree of conjugation of the serotype 8 glycoconjugates of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of serotype 9V of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 10A glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of serotype 11A glycoconjugates of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of serotype 12F of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of serotype 14 glycoconjugates of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 15B glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of serotype 18C of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 19A glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of serotype 19F of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 22F glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 23F glycoconjugate of the present invention is between 2 and 15. In a preferred embodiment, the conjugate degree of the serotype 33F glycoconjugate of the present invention is between 2 and 15. The serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, or 33F glycoconjugates of the present invention and immunogenic compositions comprising the glycoconjugates may contain free saccharides that are not covalently bound to a carrier protein but are still present in the glycoconjugate composition. The free saccharides may be non-covalently associated with the glycoconjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or with the glycoconjugate). In one embodiment, the serotype 1 glycoconjugates of the present invention contain less than about 40% free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In a preferred embodiment, the serotype 1 glycoconjugates contain less than about 20% free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In one embodiment, the serotype 1 glycoconjugates of the present invention contain less than about 40% free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In a preferred embodiment, the serotype 1 glycoconjugates contain less than about 20% free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In one embodiment, the serotype 4 glycoconjugates of the present invention contain less than about 40% free serotype 4 polysaccharide compared to the total amount of serotype 4 polysaccharide. In a preferred embodiment, the serotype 4 glycoconjugates contain less than about 30% free serotype 4 polysaccharide compared to the total amount of serotype 4 polysaccharide. In one embodiment, the serotype 5 glycoconjugates of the present invention contain less than about 45% free serotype 5 polysaccharide compared to the total amount of serotype 5 polysaccharide. In a preferred embodiment, the serotype 5 glycoconjugates contain less than about 40% free serotype 5 polysaccharide compared to the total amount of serotype 5 polysaccharide. In one embodiment, the serotype 6A glycoconjugates of the present invention contain less than about 40% free serotype 6A polysaccharide compared to the total amount of serotype 6A polysaccharide. In a preferred embodiment, the serotype 6A glycoconjugates contain less than about 30% free serotype 6A polysaccharide compared to the total amount of serotype 6A polysaccharide. In one embodiment, the serotype 6B glycoconjugates of the present invention contain less than about 30% free serotype 6B polysaccharide compared to the total amount of serotype 6B polysaccharide. In a preferred embodiment, the serotype 6B glycoconjugates contain less than about 20% free serotype 6B polysaccharide compared to the total amount of serotype 6B polysaccharide. In one embodiment, the serotype 7F glycoconjugates of the present invention contain less than about 30% free serotype 7F polysaccharide compared to the total amount of serotype 7F polysaccharide. In a preferred embodiment, the serotype 7F glycoconjugates contain less than about 20% free serotype 7F polysaccharide compared to the total amount of serotype 7F polysaccharide. In one embodiment, the serotype 8 glycoconjugates of the present invention contain less than about 30% free serotype 8 polysaccharide compared to the total amount of serotype 8 polysaccharide. In a preferred embodiment, the serotype 8 glycoconjugates contain less than about 20% free serotype 8 polysaccharide compared to the total amount of serotype 8 polysaccharide. In one embodiment, the serotype 9V glycoconjugates of the present invention contain less than about 40% free serotype 9V polysaccharide compared to the total amount of serotype 9V polysaccharide. In a preferred embodiment, the serotype 9V glycoconjugates contain less than about 35% free serotype 9V polysaccharide compared to the total amount of serotype 9V polysaccharide. In one embodiment, the serotype 10A glycoconjugates of the present invention contain less than about 40% free serotype 10A polysaccharide compared to the total amount of serotype 10A polysaccharide. In a preferred embodiment, the serotype 10A glycoconjugates contain less than about 20% free serotype 10A polysaccharide compared to the total amount of serotype 10A polysaccharide. In one embodiment, the serotype 11A glycoconjugates of the present invention contain less than about 40% free serotype 11A polysaccharide compared to the total amount of serotype 11A polysaccharide. In a preferred embodiment, the serotype 11A glycoconjugates contain less than about 30% free serotype 11A polysaccharide compared to the total amount of serotype 11A polysaccharide. In one embodiment, the serotype 12F glycoconjugates of the present invention contain less than about 40% free serotype 12F polysaccharide compared to the total amount of serotype 12F polysaccharide. In a preferred embodiment, the serotype 12F glycoconjugates contain less than about 30% free serotype 12F polysaccharide compared to the total amount of serotype 12F polysaccharide. In one embodiment, the serotype 14 glycoconjugates of the present invention contain less than about 40% free serotype 14 polysaccharide compared to the total amount of serotype 14 polysaccharide. In a preferred embodiment, the serotype 14 glycoconjugates contain less than about 35% free serotype 14 polysaccharide compared to the total amount of serotype 14 polysaccharide. In one embodiment, the serotype 15B glycoconjugates of the present invention contain less than about 40% free serotype 15B polysaccharide compared to the total amount of serotype 15B polysaccharide. In a preferred embodiment, the serotype 15B glycoconjugates contain less than about 35% free serotype 15B polysaccharide compared to the total amount of serotype 15B polysaccharide. In one embodiment, the serotype 18C glycoconjugates of the present invention contain less than about 30% free serotype 18C polysaccharide compared to the total amount of serotype 18C polysaccharide. In a preferred embodiment, the serotype 18C glycoconjugates contain less than about 20% free serotype 18C polysaccharide compared to the total amount of serotype 18C polysaccharide. In one embodiment, the serotype 19A glycoconjugates of the present invention contain less than about 40% free serotype 19A polysaccharide compared to the total amount of serotype 19A polysaccharide. In a preferred embodiment, the serotype 19A glycoconjugates contain less than about 30% free serotype 19A polysaccharide compared to the total amount of serotype 19A polysaccharide. In one embodiment, the serotype 19F glycoconjugates of the present invention contain less than about 30% free serotype 19F polysaccharide compared to the total amount of serotype 19F polysaccharide. In a preferred embodiment, the serotype 19F glycoconjugates contain less than about 20% free serotype 19F polysaccharide compared to the total amount of serotype 19F polysaccharide. In one embodiment, the serotype 22F glycoconjugates of the present invention contain less than about 40% free serotype 22F polysaccharide compared to the total amount of serotype 22F polysaccharide. In a preferred embodiment, the serotype 22F glycoconjugates contain less than about 20% free serotype 22F polysaccharide compared to the total amount of serotype 22F polysaccharide. In one embodiment, the serotype 23F glycoconjugates of the present invention contain less than about 30% free serotype 23F polysaccharide compared to the total amount of serotype 23F polysaccharide. In a preferred embodiment, the serotype 23F glycoconjugates contain less than about 20% free serotype 23F polysaccharide compared to the total amount of serotype 23F polysaccharide. In one embodiment, the serotype 33F glycoconjugates of the present invention contain less than about 30% free serotype 33F polysaccharide compared to the total amount of serotype 33F polysaccharide. In a preferred embodiment, the serotype 33F glycoconjugates contain less than about 20% free serotype 33F polysaccharide compared to the total amount of serotype 33F polysaccharide. Serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, or 33F glycoconjugates of the present invention can also be characterized by their molecular size distribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relative molecular size distribution of the conjugates. Size exclusion chromatography (SEC) is used in a gravity-fed column to determine the molecular size distribution profile of the conjugates. Large molecules, excluded from the pores in the media, elute faster than small molecules. The column eluate is collected using a fraction collector. The fractions are colorimetrically tested using a sugar assay. The column used for Kd determination is calibrated to establish a fraction (V0) that completely excludes molecules (Kd = 0) and a fraction (Vi) that represents maximum retention (Kd = 1). The fraction (Ve) that achieves a specific sample attribute is related to Kd by the equation Kd=(Ve-V0) / (Vi-V0). In one embodiment, at least 40% of serotype 1 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 50% of serotype 1 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 50% and 80% of serotype 1 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 30% of the serotype 4 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 40% and 80% of the serotype 4 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 40% of the serotype 5 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 55% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 55% and 80% of the serotype 5 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 50% of the serotype 6A glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 60% of the glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a more preferred embodiment, between 60% and 90% of the serotype 6A glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In one embodiment, at least 30% of the serotype 6B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 35% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 35% and 80% of the serotype 6B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 50% of the serotype 7F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 65% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 65% and 90% of the serotype 7F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 60% of the serotype 8 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 70% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 70% and 90% of the serotype 8 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 30% of the serotype 9V glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the serotype 9V glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In an even more preferred embodiment, between 40% and 80% of the serotype 9V glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In one embodiment, at least 40% of serotype 10A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 55% of serotype 10A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 55% and 85% of serotype 10A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 50% of serotype 11A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 60% of serotype 11A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 60% and 85% of serotype 11A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 40% of the serotype 12F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 50% and 80% of the serotype 12F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 40% of the serotype 14 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 50% and 80% of the serotype 14 glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 30% of the serotype 15B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 40% and 80% of the serotype 15B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 30% of the serotype 18C glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 40% and 80% of the serotype 18C glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 40% of serotype 19A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 50% of serotype 19A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 50% and 80% of serotype 19A glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 40% of the serotype 19F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 50% and 80% of the serotype 19F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 30% of the serotype 22F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 40% and 80% of the serotype 22F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 30% of the serotype 23F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 35% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 35% and 80% of the serotype 23F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, at least 50% of the serotype 33F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 60% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 60% and 95% of the serotype 33F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F saccharides are activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form cyanate esters. The activated polysaccharides can then be coupled directly or via a spacer (linker) group to an amine group on a carrier protein. For example, the spacer may be cystamine or cysteamine, which gives a thiolated polysaccharide that can be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl)aminobenzoate (S1AB), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfoSIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino]propionate (SBAP)). Cyanate esters are preferably coupled with hexamethylenediamine or adipic acid dihydrazide (ADH), and amine-derivatized sugars are coupled to carrier proteins (e.g., CRMs) via carboxyl groups on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. 197 Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348 and WO 96 / 129094. Other suitable techniques for conjugation include the use of carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, and TSTU. Many of these techniques are described in International Patent Application Publication No. WO 98 / 42721. Conjugation can involve a carbonyl linker, which can be formed by reacting the free hydroxyl groups of the sugar with 1,1'-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with the protein to form a carbamate linkage. This can involve reducing the mutarotomer terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amine group on the protein. In one embodiment, serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F glycoconjugates of the invention are prepared using reductive amination chemistry. According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of the purified saccharide, and (2) reduction of the activated saccharide and a carrier protein to form a glycoconjugate (see, e.g., WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F glycoconjugates of the invention are prepared using reductive amination chemistry. In another embodiment, serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F and 23F glycoconjugates of the invention are prepared using reductive amination chemistry. As described above, size fractionation of the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F capsular polysaccharides may be performed to a target molecular weight (MW) range prior to oxidation. Thus, in one embodiment, the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F capsular polysaccharides are size fractionated prior to oxidation. Thus, in one embodiment, isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides are size fractionated prior to oxidation. In one embodiment, isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide is conjugated to a carrier protein by a process comprising the following steps: (a) reacting the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide with an oxidizing agent to produce an activated polysaccharide; (b) complexing the activated polysaccharide of step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. After the oxidation step (a), the sugars are considered activated and are referred to as "activated polysaccharides." In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4- ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In one embodiment, isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F capsular polysaccharides are reacted with periodate. In one embodiment, isolated serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 18C, 19A, 19F, 22F, and 23F capsular polysaccharides are reacted with periodate. In a preferred embodiment, the oxidant is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In a most preferred embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F polysaccharide with periodate. In one embodiment, step a) comprises reacting serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F polysaccharide with 0.05 to 2 molar equivalents of periodate. In one embodiment, step a) comprises reacting serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F polysaccharide with 0.05 to 0.2 molar equivalents of periodate. In one embodiment, step a) comprises reacting serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F polysaccharide with 0.2 to 0.5 molar equivalents of periodate. In one embodiment, step a) comprises reacting serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F polysaccharide with 0.5 to 1.5 molar equivalents of periodate. In one embodiment, step a) comprises reacting serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F polysaccharide with 1.5 to 2.0 molar equivalents of periodate. In some embodiments, the reaction of step (a) is quenched. Thus, after step (a), step (a') may be performed (see WO2015110940). Thus, in one embodiment, the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide is bound to a carrier protein by a process comprising the following steps: (a) reacting the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide with an oxidizing agent to produce an activated polysaccharide; (a') quenching the oxidation reaction by adding a quenching agent to obtain an activated polysaccharide; (b) complexing the activated saccharide of step (a') with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. In one embodiment, the oxidizing agent is a 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) free radical and N-chlorosuccinimide (NCS) as a co-oxidant. This oxidizing agent is particularly suitable for oxidizing serotype 12F capsular polysaccharide. In this embodiment, a glycoconjugate from Streptococcus pneumoniae serotype 12F is prepared by oxidizing the primary alcohol of the saccharide to an aldehyde using a 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) free radical and N-chlorosuccinimide (NCS) as a co-oxidant (hereinafter referred to as "TEMPO / NCS oxidation"), as described in Example 7 and WO 2014 / 097099. Therefore, in one aspect, the glycoconjugate from Streptococcus pneumoniae serotype 12F of the present invention is obtained by a method comprising the following steps: (a) reacting isolated serotype 12F capsular polysaccharide with 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and N-chlorosuccinimide (NCS) to produce an activated polysaccharide; (b) complexing the activated polysaccharide from step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate (hereinafter referred to as "TEMPO / NCS-reductive amination"). In one aspect, the glycoconjugate from Streptococcus pneumoniae serotype 12F is obtained by this method. In one embodiment, isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F capsular polysaccharides are reacted with periodate and isolated serotype 12F capsular polysaccharide is reacted with TEMPO / NCS. In one embodiment, isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 18C, 19A, 19F, 22F, and 23F capsular polysaccharides are reacted with periodate and isolated serotype 12F capsular polysaccharide is reacted with TEMPO / NCS. In a preferred embodiment, the degree of oxidation of the activated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F polysaccharide (also referred to as the "activation degree" in this document) is between 2 and 30. In one embodiment, when the carrier protein is TT, the degree of oxidation of the activated serotype 1 polysaccharide is between 1 and 15 (see, for example, Table 2 of WO2019 / 152921). In a preferred embodiment, when the carrier protein is CRM 197When activated, the degree of oxidation of serotype 1 polysaccharide is between 4 and 10. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 4 polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 4 polysaccharide is between 1 and 5. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 5 polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 5 polysaccharide is between 2 and 6. See Table 1 of WO2019 / 152921. In one embodiment, when the carrier protein is TT, the degree of oxidation of the activated serotype 5 polysaccharide is between 1 and 15. See Table 2 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 6A polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 6A polysaccharide is between 5 and 15. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 6B polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 6B polysaccharide is between 7 and 13. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 7F polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 7F polysaccharide is between 2 and 8. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 8 polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 8 polysaccharide is between 1 and 17. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 9V polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 9V polysaccharide is between 4 and 9. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 10A polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 10A polysaccharide is between 1 and 12. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 11A polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 11A polysaccharide is between 1 and 15. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 12F polysaccharide is between 1 and 15. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 12F polysaccharide is between 1 and 9. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 14 polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 14 polysaccharide is between 6 and 13. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 15B polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 15B polysaccharide is between 1 and 17. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 15B polysaccharide is between 1 and 15 when the carrier protein is TT. See Table 2 of WO2019 / 152925. In one embodiment, the oxidation degree of the activated serotype 18C polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 18C polysaccharide is between 6 and 14. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 19A polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 19A polysaccharide is between 7 and 13. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 19F polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 19F polysaccharide is between 6 and 12. See Table 1 of WO2019 / 152921. In one embodiment, the number of activated serotype 22F polysaccharides is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 22F polysaccharide is between 1 and 16. See Table 1 of WO2019 / 152921. In one embodiment, when the carrier protein is TT, the degree of oxidation of the activated serotype 22F polysaccharide is between 1 and 20. See Table 2 of WO2019 / 152925. In one embodiment, the oxidation degree of the activated serotype 23F polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of serotype 23F polysaccharide is between 6 and 14. See Table 1 of WO2019 / 152921. In one embodiment, the oxidation degree of the activated serotype 33F polysaccharide is between 1 and 20. In a preferred embodiment, when the carrier protein is CRM 197 When activated, the degree of oxidation of the serotype 33F polysaccharide is between 1 and 15. See Table 1 of WO2019 / 152921. The activated polysaccharide and carrier protein can be lyophilized separately (separate lyophilization) or lyophilized together (co-lyophilization) (freeze drying). In one embodiment, the activated polysaccharide and carrier protein are lyophilized together. In another embodiment, the activated polysaccharide and carrier protein are lyophilized separately. In one embodiment, lyophilization occurs in the presence of non-reducing sugars. Possible non-reducing sugars include sucrose, cocoa, raffinose, stachyose, melezitose, polydextrose, mannitol, lactitol, and palatinit. In one embodiment, the initial input ratio (weight / weight) of activated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide to carrier protein in step b) is between 4: 1 and 0.1: 1. In one embodiment, the initial input ratio (weight / weight) of activated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide to carrier protein is between 1.5: 1 and 0.5: 1. In one embodiment, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in a solution consisting essentially of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in a DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. In one embodiment, the reduction reaction (c) for serotypes 6A, 6B, 7F, 8, 10A, 15B, 19A, 19F, 22F and 23F is carried out in DMSO (dimethyl sulfoxide) solvent and the reduction reaction (c) for serotypes 1, 4, 5, 9V, 11A, 12F, 14 and 18C is carried out in an aqueous solvent. In one embodiment, the reduction reaction (c) for serotypes 6A, 6B, 7F, 8, 10A, 15B, 19A, 19F, 22F and 23F is carried out in DMSO (dimethyl sulfoxide) solvent and the reduction reaction (c) for serotypes 1, 4, 5, 9V, 11A, 12F, 14, 18C and 33F is carried out in an aqueous solvent. In one embodiment, the reduction reaction (c) for serotypes 6A, 6B, 7F, 18C, 19A, 19F and 23F is carried out in DMSO (dimethyl sulfoxide) solvent and the reduction reaction (c) for serotypes 1, 4, 5, 9V, 14, 22F and 33F is carried out in an aqueous solvent. In one embodiment, the reduction reaction (c) for serotypes 6A, 6B, 7F, 11A, 12F, 19A, 19F and 23F is carried out in DMSO (dimethyl sulfoxide) solvent and the reduction reaction (c) for serotypes 1, 4, 5, 8, 9V, 10A, 14, 15B, 18C, 22F and 33F is carried out in an aqueous solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Bude acid or a Lewis acid, an amine borane, such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In one embodiment, between 0.2 and 10 molar equivalents of reducing agent are used in step c). Preferably, between 0.5 and 5 molar equivalents of reducing agent are used in step c). At the end of the reduction reaction, unreacted aldehyde groups may remain in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation to a carrier protein, serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F glycoconjugates can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. These techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Thus, in one embodiment, the process for producing the serotype 1 glycoconjugates of the present invention includes a step of purifying the glycoconjugate after production. In certain embodiments, the serotype 33F glycoconjugates of the present invention are prepared using reductive amination. In other embodiments, the serotype 33F glycoconjugates of the present invention are prepared using eTEC conjugation (hereinafter "serotype 33F eTEC-bound glycoconjugates"), such as described in WO 2014 / 027302 or WO 2015110941 (see Examples 1, 2, and 3). The 33F glycoconjugate comprises a saccharide covalently bound to a carrier protein via one or more eTEC spacers, wherein the saccharide is covalently bound to the eTEC spacer via a carbamate linkage, and wherein the carrier protein is covalently bound to the eTEC spacer via an amide linkage. The eTEC-bound glycoconjugates of the present invention can be represented by the general formula (III): The atoms that make up the eTEC spacer are contained in the middle box. The eTEC spacer consists of seven linear atoms (i.e., -C(O)NH(CH 2) 2SCH 2C(O)-) and provide stable thioether and amide bonds between the sugar and the carrier protein. The synthesis of eTEC-linked glycoconjugates involves the reaction of activated hydroxyl groups of the sugar with an amine group of a sulfanylamine reagent (e.g., cystamine or cysteine amine or a salt thereof) to form a carbamate linkage to the sugar to provide a thiolated sugar. Generation of one or more free sulfhydryl groups is accomplished by reaction with a reducing agent to provide an activated thiolated sugar. Reaction of the free sulfhydryl groups of the activated thiolated sugar with an activated carrier protein having one or more α-haloacetamide groups on an amine-containing residue generates a thioether bond for conjugate formation, wherein the carrier protein is linked to the eTEC spacer via an amide bond. In the serotype 33 FeTEC-linked glycoconjugates of the present invention, the saccharide may be a polysaccharide or an oligosaccharide. The carrier protein may be selected from any suitable carrier as described herein or known to those skilled in the art. The saccharide is preferably a polysaccharide. In some of these embodiments, the carrier protein is a CRM. 197 In some of these embodiments, the eTEC-linked glycoconjugate comprises S. pneumoniae serotype 33F capsular polysaccharide. In a particularly preferred embodiment, the eTEC-linked glycoconjugate comprises Pn-33F capsular polysaccharide, which is bound to the CRM via an eTEC spacer. 197 Covalently bound (glycoconjugate linked via serotype 33F eTEC). In one embodiment, serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, and 23F glycoconjugates of the present invention are prepared using reductive amination chemistry, and serotype 33F glycoconjugates of the present invention are prepared using eTEC conjugation. 1.5 S. pneumoniae serotype 15A glycoconjugates of the present invention In one aspect, the present invention relates to glycoconjugates of Streptococcus pneumoniae serotype 15A. The structure of the S. pneumoniae serotype 15A polysaccharide is known in the art (see, eg, Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899). In one embodiment, the capsular S. pneumoniae serotype 15A saccharide used in the present invention is a synthetic carbohydrate. However, in a preferred embodiment, the source of bacterial polysaccharides according to the present invention can be Streptococcus pneumoniae serotype 15A bacterial cells. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 15A polysaccharides can be obtained from established culture collections (such as, for example, the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical samples. Serotype 15A saccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art. They can also be obtained commercially, such as from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., Reference No. ATCC (537-X)). If the serotype 15A saccharide is obtained directly from bacteria, the bacterial cells can be grown in a culture medium (preferably a soy-based culture medium). After fermentation of the bacterial cells producing the S. pneumoniae serotype 15A capsular polysaccharide, the bacterial cells can be lysed to produce a cell lysate. The serotype 15A polysaccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, deep filtration, precipitation, ultrafiltration, treatment with activated carbon, diafiltration and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 15A capsular polysaccharide can then be used to prepare glycoconjugates. Isolated serotype 15A capsular saccharides obtained by purifying serotype 15A polysaccharides from S. pneumoniae cell lysates and optionally size fractionating the purified polysaccharides can be characterized by various parameters including, for example, weight average molecular weight (Mw). The molecular weight of polysaccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In preferred embodiments, the isolated serotype 15A capsular polysaccharide (i.e., purified prior to further processing) has a weight average molecular weight between 100 kDa and 2500 kDa. In one embodiment, the isolated serotype 15A capsular polysaccharide has a weight average molecular weight between 250 kDa and 1500 kDa. In one embodiment, the isolated serotype 15A capsular polysaccharide has a weight average molecular weight between 500 kDa and 1000 kDa. Any integer within any of the above ranges is contemplated as an embodiment of the present disclosure. To produce serotype 15A conjugates with favorable filterability characteristics, immunogenicity, and / or yield, polysaccharide size fractionation to a target molecular weight range can be performed prior to conjugation to a carrier protein. It is desirable to reduce the size of the purified serotype 15A polysaccharide while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used. In one embodiment, the size of the purified serotype 15A polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis may be performed using a weak acid (e.g., acetic acid, formic acid, propionic acid). Chemical hydrolysis may also be performed using a diluted strong acid (e.g., diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitric acid, or diluted perchloric acid). However, the size of the purified serotype 15A polysaccharide can preferably be reduced by mechanical homogenization. In one embodiment, the size of the purified serotype 15A polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate is increased by using a higher applied homogenization pressure, and the exposure time can be increased by recirculating the feed stream through the homogenizer. In one embodiment, the isolated serotype 15A capsular polysaccharide is size-fractionated to a weight average molecular weight between 50 kDa and 500 kDa. In a preferred embodiment, the isolated serotype 15A capsular polysaccharide is size-fractionated to a weight average molecular weight between 75 kDa and 250 kDa. The isolated serotype 15A capsular polysaccharide is preferably size-fractionated to a weight average molecular weight of less than 175 kDa. In an even more preferred embodiment, the isolated serotype 15A capsular polysaccharide is size-fractionated to a weight average molecular weight between 75 kDa and 175 kDa. In a most preferred embodiment, the isolated serotype 15A capsular polysaccharide is size-fractionated to a weight average molecular weight between 100 kDa and 175 kDa. The isolated serotype 15A polysaccharide is preferably size-fractionated by mechanical homogenization, preferably by high-pressure homogenization. In one embodiment, the isolated serotype 15A capsular polysaccharide is not size fractionated. In one embodiment, the isolated serotype 15A capsular polysaccharide has a weight average molecular weight of between 50 kDa and 500 kDa before binding. In one embodiment, the isolated serotype 15A capsular polysaccharide has a weight average molecular weight of between 75 kDa and 250 kDa before binding. In a preferred embodiment, the isolated serotype 15A capsular polysaccharide has a weight average molecular weight of between 75 kDa and 175 kDa before binding. In an even more preferred embodiment, the isolated serotype 15A capsular polysaccharide has a weight average molecular weight of between 90 kDa and 150 kDa before binding. In a most preferred embodiment, the isolated serotype 15A capsular polysaccharide has a weight average molecular weight of between 100 kDa and 175 kDa before binding. The weight average molecular weight (Mw) of the saccharide prior to conjugation refers to the Mw of the polysaccharide prior to activation (i.e., after the final size fractionation step but before the polysaccharide is reacted with the activating agent). In the context of the present invention, the Mw of the 15A polysaccharide is not substantially modified by the activation step, and the Mw of the 15A polysaccharide incorporated into the conjugate is similar to the Mw of the polysaccharide measured prior to activation. In one embodiment, the serotype 15A saccharide conjugates of the present invention comprise serotype 15A capsular polysaccharide, wherein the polysaccharide has a weight-average molecular weight (Mw) of between 50 kDa and 500 kDa prior to conjugation. In one embodiment, the weight-average molecular weight (Mw) is between 75 kDa and 250 kDa. In a preferred embodiment, the weight-average molecular weight (Mw) is between 75 kDa and 175 kDa. In a most preferred embodiment, the weight-average molecular weight (Mw) is between 90 kDa and 150 kDa. In some embodiments, the serotype 15A glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 10,000 kDa. In other embodiments, the serotype 15A glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 10,000 kDa. Preferably, the serotype 15A glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 6,000 kDa. The serotype 15A glycoconjugates of the present invention can also be characterized by the sugar to carrier protein ratio (weight / weight). In some embodiments, the serotype 15A polysaccharide to carrier protein ratio (w / w) in the glycoconjugate is between 0.5 and 3.0. The sugar to carrier protein ratio (w / w) is preferably between 0.5 and 1.5. Even more preferably, the sugar to carrier protein ratio (w / w) is between 0.7 and 1.1. Another way to characterize the serotype 15A glycoconjugates of the present invention is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) to which the saccharide is bound. The saccharide can be characterized by the range of bound lysine residues (degree of binding). Evidence of lysine modification of the carrier protein due to covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Binding results in a reduction in the number of recovered lysine residues compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the degree of binding of the serotype 15A glycoconjugates of the present invention is between 2 and 20. Preferably, the degree of binding of the serotype 15A glycoconjugates of the present invention is between 5 and 10. The serotype 15A glycoconjugates and immunogenic compositions of the present invention may contain free saccharides that are not covalently bound to a carrier protein but are still present in the glycoconjugate composition. The free saccharides may be non-covalently associated with the glycoconjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or with the glycoconjugate). In one embodiment, the serotype 15A glycoconjugate comprises less than about 40% free serotype 15A polysaccharide compared to the total amount of serotype 15A polysaccharide. In a preferred embodiment, the serotype 15A glycoconjugate comprises less than about 25% free serotype 15A polysaccharide compared to the total amount of serotype 15A polysaccharide. Serotype 15A glycoconjugates can also be characterized by their molecular size distribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relative molecular size distribution of conjugates. Size exclusion chromatography (SEC) is used in gravity-fed columns to determine the molecular size distribution profile of the conjugates. Large molecules, excluded from the pores in the media, elute faster than small molecules. The column eluate is collected using a fraction collector. The fractions are colorimetrically tested using a sugar assay. The column used for Kd determination is calibrated to establish the fraction (V0) of molecules that are completely excluded (Kd = 0) and the fraction (Vi) representing maximum retention (Kd = 1). The fraction (Ve) that achieves a specific sample attribute is related to the Kd using the equation Kd = (Ve - V0) / (Vi - V0). In one embodiment, at least 40% of the serotype 15A glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In an even more preferred embodiment, between 50% and 90% of the serotype 15A glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In one embodiment, the serotype 15A sugar is activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate. The activated sugar can then be linked directly or via a spacer (linker) group to a carrier protein (preferably CRM). 197 ). For example, the spacer may be cystamine or cysteamine, which gives a thiolated polysaccharide that can be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl)aminobenzoate (S1AB), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfoSIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino]propionate (SBAP)). Cyanate esters are preferably coupled with hexamethylenediamine or adipic acid dihydrazide (ADH), and amine-derivatized sugars are coupled to carrier proteins (e.g., CRMs) via carboxyl groups on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. 197 Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348 and WO 96 / 129094. Other suitable techniques for conjugation include the use of carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, and TSTU. Many of these techniques are described in International Patent Application Publication No. WO 98 / 42721. Conjugation can involve a carbonyl linker, which can be formed by reacting the free hydroxyl groups of the sugar with 1,1'-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with the protein to form a carbamate linkage. This can involve reducing the mutarotomer terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amine group on the protein. In a preferred embodiment, the serotype 15A glycoconjugates of the present invention are prepared using reductive amination chemistry. According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of the purified saccharide, and (2) reduction of the activated saccharide and carrier protein to form the glycoconjugate (see, e.g., WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, the serotype 15A glycoconjugate of the present invention is prepared by conjugating isolated serotype 15A capsular polysaccharide to a carrier protein in a process comprising the following steps: (a) reacting the isolated serotype 15A capsular polysaccharide with an oxidizing agent; (b) complexing the activated polysaccharide of step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As described above, size fractionation of the isolated serotype 15A capsular polysaccharide to a target molecular weight (MW) range may be performed prior to oxidation. Thus, in one embodiment, the isolated serotype 15A capsular polysaccharide is size fractionated prior to oxidation. In one embodiment, the isolated serotype 15A capsular polysaccharide is not size fractionated prior to oxidation. In one embodiment, the oxidation step (a) is performed at a pH between 4.0 and 6.0. Preferably, the oxidation step (a) is performed at a pH between 4.5 and 5.5. In one embodiment, the oxidation step (a) is performed at a pH of about 5.0. After the oxidation step (a), the sugars are considered activated and are referred to as "activated polysaccharides." In one embodiment, the activated serotype 15A polysaccharide of the present invention has a weight average molecular weight (Mw) between 50 kDa and 500 kDa. In another embodiment, the weight average molecular weight (Mw) is between 75 kDa and 250 kDa. In a preferred embodiment, the weight average molecular weight (Mw) is between 75 kDa and 175 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 90 kDa and 150 kDa. In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4- ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In a preferred embodiment, the oxidant is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In a most preferred embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.1 to 2 molar equivalents of periodate. Preferably, step a) comprises reacting the polysaccharide with 0.5 to 1.5 molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharide with 0.8 to 1.2 molar equivalents of periodate. In one embodiment, the degree of oxidation of the activated serotype 15A polysaccharide (also referred to herein as "activation degree") is between 2 and 20. In a preferred embodiment, the degree of oxidation of the activated serotype 15A polysaccharide is between 2 and 8. In the most preferred embodiment, the degree of oxidation of the activated serotype 15A polysaccharide is 5±2.5. In one embodiment, the activated serotype 15A polysaccharide and the carrier protein are lyophilized before step b). Lyophilization preferably occurs after step a). In one embodiment, the activated polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized. In one embodiment, the activated serotype 15A polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized, and the activated polysaccharide and the carrier protein are re-dissolved in the same solution. In one embodiment, the activated serotype 15A polysaccharide and the carrier protein are lyophilized separately (separate lyophilization). In one embodiment, the activated serotype 15A polysaccharide and the carrier protein are lyophilized together (co-lyophilization). In one embodiment, lyophilization occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, molasses, raffinose, stachyose, melezitose, polydextrose, mannitol, lactitol, and isomaltulose. In one embodiment, the sugar is selected from the group consisting of sucrose, molasses, and mannitol. In one embodiment, the sugar is sucrose, molasses, or mannitol. In one embodiment, the sugar is sucrose. In one embodiment, the initial input ratio (weight / weight) of activated serotype 15A capsular polysaccharide to carrier protein in step b) is between 3:1 and 0.5:1. In one embodiment, the initial input ratio (weight / weight) of activated serotype 15A capsular polysaccharide to carrier protein is between 1.5:1 and 0.5:1. The initial input ratio (weight / weight) of activated serotype 15A capsular polysaccharide to carrier protein is preferably between 1.1:1 and 0.9:1. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. Preferably, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulfoxide (DMSO) or dimethylformamide (DMF). The reduction reaction (c) is preferably carried out in the presence of dimethylsulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) or DMF (dimethylformamide) solvent. The reduction reaction (c) is best carried out in DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Burkholderia acid or a Lewis acid, an amine borane, such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of reducing agent are used in step c). Preferably, between 0.5 and 2 molar equivalents of reducing agent are used in step c). Optimally, between 0.9 and 1.1 molar equivalents of reducing agent are used in step c). At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH 4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation to the carrier protein, the serotype 15A glycoconjugate can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. Such techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Thus, in one embodiment, the process for producing the serotype 15A glycoconjugate of the present invention includes a step of purifying the glycoconjugate after production. 1.6 S. pneumoniae serotype 23A glycoconjugates of the present invention In one aspect, the present invention relates to glycoconjugates of Streptococcus pneumoniae serotype 23A. The structure of the S. pneumoniae serotype 23A polysaccharide is known in the art (see, for example, Ravenscroft N et al. (2017) Carbohydrate Res. Vol. 450, p 19-29 and WO2019050814). The structure of the serotype 23A capsular polysaccharide is: →4)-β-D-Glc p-(1→3)-[[α-L-Rha p-(1→2)]-[Gro-(2→P→3)]-β-D-Gal p-(1→4)]-β-L-Rha p-(1→. In one embodiment, the capsular Streptococcus pneumoniae serotype 23A saccharide used in the present invention is a synthetic carbohydrate. However, in a preferred embodiment, the source of bacterial polysaccharides according to the present invention can be Streptococcus pneumoniae serotype 23A bacterial cells. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 23A polysaccharides can be obtained from established culture collections (such as, for example, the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical samples. Serotype 23A saccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art. They can also be obtained commercially, such as from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., Reference No. ATCC 545-X, No. ATCC 546-X, No. ATCC 547-X). If the serotype 23A saccharide is obtained directly from bacteria, the bacterial cells can be grown in a culture medium (preferably in a soy-based culture medium). After fermentation of the bacterial cells producing the S. pneumoniae serotype 23A capsular polysaccharide, the bacterial cells can be dissolved to produce a cell lysate. The serotype 23A polysaccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, deep filtration, precipitation, ultrafiltration, treatment with activated carbon, diafiltration and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 23A capsular polysaccharide can then be used to prepare glycoconjugates. Isolated serotype 23A capsular saccharides obtained by purifying serotype 23A polysaccharides from S. pneumoniae cell lysates and optionally size fractionating the purified polysaccharides can be characterized by various parameters including, for example, weight average molecular weight (Mw). The molecular weight of polysaccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In preferred embodiments, the isolated serotype 23A capsular polysaccharide (i.e., purified prior to further processing) has a weight average molecular weight between 100 kDa and 2500 kDa. In one embodiment, the isolated serotype 23A capsular polysaccharide has a weight average molecular weight between 250 kDa and 1500 kDa. In one embodiment, the isolated serotype 23A capsular polysaccharide has a weight average molecular weight between 500 kDa and 1000 kDa. Any integer within any of the above ranges is contemplated as an embodiment of the present disclosure. To produce serotype 23A conjugates with favorable filterability characteristics, immunogenicity, and / or yield, size fractionation of the polysaccharide to a target molecular weight range can be performed prior to conjugation to the carrier protein. It is desirable to reduce the size of the purified serotype 23A polysaccharide while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used. The size of purified serotype 23A polysaccharide is best reduced by mechanical homogenization. It has not been found suitable to use acid hydrolysis to reduce the size of serotype 23A polysaccharides, as suggested in WO2019050814 or WO2019050818. It has been found that acid hydrolysis can affect the structural integrity of the serotype 23A polysaccharide. It has been found that even relatively mild hydrolysis (e.g., treatment with 100 mM acetic acid at 80°C for 2 hours) results in 25% branched rhamnose (α-L-Rha p-(1→2)) loss (see Figure 1). Mechanical size fractionation does not release this residue, which is important from an immunological point of view. In addition, this residue is the primary activation site for periodate oxidation. Therefore, if periodate oxidation of polysaccharides is used (e.g., as an activation step in reductive amination chemistry), it is important to retain this residue. Therefore, in a preferred embodiment, the size of the purified serotype 23A polysaccharide is reduced by mechanical homogenization. In one embodiment, the size of the purified serotype 23A polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through sufficiently small flow paths. The shear rate is increased by using a higher applied homogenization pressure, and the exposure time can be increased by recirculating the feed stream through the homogenizer. In a preferred embodiment, the process for preparing the serotype 23A glycoconjugates of the present invention does not include a size fractionation step of the serotype 23A polysaccharide by acid hydrolysis. In one embodiment, the isolated serotype 23A capsular polysaccharide is size-fractionated to a weight average molecular weight between 50 kDa and 500 kDa. In a preferred embodiment, the isolated serotype 23A capsular polysaccharide is size-fractionated to a weight average molecular weight between 75 kDa and 400 kDa. In an even more preferred embodiment, the isolated serotype 23A capsular polysaccharide is size-fractionated to a weight average molecular weight between 100 kDa and 350 kDa. In a most preferred embodiment, the isolated serotype 23A capsular polysaccharide is size-fractionated to a weight average molecular weight between 125 kDa and 225 kDa. The isolated serotype 23A polysaccharide is preferably size-fractionated by mechanical homogenization, most preferably by high pressure homogenization. In one embodiment, the isolated serotype 23A capsular polysaccharide is not size fractionated. In one embodiment, the isolated serotype 23A capsular polysaccharide has a weight average molecular weight of between 50 kDa and 500 kDa before binding. In one embodiment, the isolated serotype 23A capsular polysaccharide has a weight average molecular weight of between 75 kDa and 400 kDa before binding. In an even more preferred embodiment, the isolated serotype 23A capsular polysaccharide has a weight average molecular weight of between 100 kDa and 350 kDa before binding. In a most preferred embodiment, the isolated serotype 23A capsular polysaccharide has a weight average molecular weight of between 125 kDa and 225 kDa before binding. The weight average molecular weight (Mw) of the saccharide prior to conjugation refers to the Mw of the polysaccharide prior to activation (i.e., after the final size fractionation step but before the polysaccharide is reacted with the activating agent). In the context of the present invention, the Mw of the 23A polysaccharide is not substantially modified by the activation step, and the Mw of the 23A polysaccharide incorporated into the conjugate is similar to the Mw of the polysaccharide measured prior to activation. In one embodiment, the serotype 23A saccharide conjugates of the present invention comprise serotype 23A capsular polysaccharide, wherein the polysaccharide has a weight average molecular weight (Mw) of between 50 kDa and 400 kDa prior to conjugation. In another embodiment, the weight average molecular weight (Mw) is between 100 kDa and 300 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 120 kDa and 240 kDa. In some embodiments, the serotype 23A glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 10,000 kDa. In other embodiments, the serotype 23A glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 7,500 kDa. Preferably, the serotype 23A glycoconjugates have a weight average molecular weight (Mw) between 2,000 kDa and 5,000 kDa. The serotype 23A glycoconjugates of the present invention can also be characterized by the sugar to carrier protein ratio (weight / weight). In some embodiments, the serotype 23A polysaccharide to carrier protein ratio (w / w) in the glycoconjugate is between 0.5 and 3.0. The sugar to carrier protein ratio (w / w) is preferably between 0.7 and 1.5. Even more preferably, the sugar to carrier protein ratio (w / w) is between 0.8 and 1.4. Another way to characterize the serotype 23A glycoconjugates of the present invention is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) to which the saccharide is bound. The saccharide can be characterized by the range of bound lysine residues (degree of binding). Evidence of lysine modification of the carrier protein due to covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Binding results in a reduction in the number of recovered lysine residues compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the degree of binding of the serotype 23A glycoconjugates of the present invention is between 2 and 20. Preferably, the degree of binding of the serotype 23A glycoconjugates of the present invention is between 5 and 15. The serotype 23A glycoconjugates and immunogenic compositions of the present invention may contain free saccharides that are not covalently bound to a carrier protein but are still present in the glycoconjugate composition. The free saccharides may be non-covalently associated with the glycoconjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or with the glycoconjugate). In one embodiment, the serotype 23A glycoconjugate comprises less than about 40% free serotype 23A polysaccharide compared to the total amount of serotype 23A polysaccharide. In a preferred embodiment, the serotype 23A glycoconjugate comprises less than about 25% free serotype 23A polysaccharide compared to the total amount of serotype 23A polysaccharide. Serotype 23A glycoconjugates can also be characterized by their molecular size distribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relative molecular size distribution of conjugates. Size exclusion chromatography (SEC) is used in gravity-fed columns to determine the molecular size distribution profile of the conjugates. Large molecules, excluded from the pores in the media, elute faster than small molecules. The column eluate is collected using a fraction collector. The fractions are colorimetrically tested using a sugar assay. The column used for Kd determination is calibrated to establish the fraction (V0) of molecules that are completely excluded (Kd = 0) and the fraction (Vi) representing maximum retention (Kd = 1). The fraction (Ve) that achieves a specific sample attribute is related to the Kd using the equation Kd = (Ve - V0) / (Vi - V0). In one embodiment, at least 40% of the serotype 23A glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a more preferred embodiment, between 50% and 90% of the serotype 23A glycoconjugates have a Kd of less than or equal to 0.3 in a CL-4B column. Serotype 23A glycoconjugates can also be characterized by the amount of branched rhamnose residues remaining in the 23A polysaccharide. As mentioned above, serotype 23A polysaccharide has been found to release branched rhamnose residues (see Figure 1). Thus, in one embodiment, the S. pneumoniae serotype 23A saccharide conjugates of the present invention comprise S. pneumoniae serotype 23A capsular polysaccharide wherein the S. pneumoniae serotype 23A capsular polysaccharide has a branched rhamnose content of greater than 75% when compared to a native S. pneumoniae serotype 23A capsular polysaccharide wherein the branched rhamnose content is considered to be about 100%. In one embodiment, the S. pneumoniae serotype 23A saccharide conjugates of the present invention comprise S. pneumoniae serotype 23A capsular polysaccharide wherein the branched rhamnose content is considered to be about 100%. The S. pneumoniae serotype 23A glycoconjugates of the present invention preferably comprise S. pneumoniae serotype 23A capsular polysaccharide wherein the S. pneumoniae serotype 23A capsular polysaccharide has a branched rhamnose content of greater than 95% when compared to native S. pneumoniae serotype 23A capsular polysaccharide wherein the branched rhamnose content is considered to be about 100%. In a preferred embodiment, the S. pneumoniae serotype 23A glycoconjugates of the present invention comprise S. pneumoniae serotype 23A capsular polysaccharide wherein the S. pneumoniae serotype 23A capsular polysaccharide has a branched rhamnose content of about 100% when compared to native S. pneumoniae serotype 23A capsular polysaccharide wherein the branched rhamnose content is considered to be about 100%. In one embodiment, the serotype 23A sugar is activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate. The activated sugar can then be linked directly or via a spacer (linker) group to a carrier protein (preferably CRM). 197 ). For example, the spacer may be cystamine or cysteamine, which gives a thiolated polysaccharide that can be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl)aminobenzoate (S1AB), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfoSIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino]propionate (SBAP)). Cyanate esters are preferably coupled with hexamethylenediamine or adipic acid dihydrazide (ADH), and amine-derivatized sugars are coupled to carrier proteins (e.g., CRMs) via carboxyl groups on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. 197 Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348 and WO 96 / 129094. Other suitable techniques for conjugation include the use of carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, and TSTU. Many of these techniques are described in International Patent Application Publication No. WO 98 / 42721. Conjugation can involve a carbonyl linker, which can be formed by reacting the free hydroxyl groups of the sugar with 1,1'-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with the protein to form a carbamate linkage. This can involve reducing the mutarotomer terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amine group on the protein. In a preferred embodiment, the serotype 23A glycoconjugates of the present invention are prepared using reductive amination chemistry. According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of the purified saccharide, and (2) reduction of the activated saccharide and carrier protein to form the glycoconjugate (see, e.g., WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, the serotype 23A glycoconjugate of the present invention is prepared by conjugating isolated serotype 23A capsular polysaccharide to a carrier protein in a process comprising the following steps: (a) reacting the isolated serotype 23A capsular polysaccharide with an oxidizing agent; (b) complexing the activated polysaccharide of step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As described above, size fractionation of the isolated serotype 23A capsular polysaccharide to a target molecular weight (MW) range may be performed prior to oxidation. Thus, in one embodiment, the isolated serotype 23A capsular polysaccharide is size fractionated prior to oxidation. In a preferred embodiment, the size of the isolated serotype 23A capsular polysaccharide can be reduced by mechanical homogenization. In one embodiment, the size of the isolated serotype 23A polysaccharide is reduced by high pressure homogenization. In a most preferred embodiment, the isolated serotype 23A capsular polysaccharide is not size-fractionated by acid hydrolysis. In one embodiment, the isolated serotype 23A capsular polysaccharide is not size fractionated prior to oxidation. In one embodiment, the oxidation step (a) is performed at a pH between 4.5 and 6.5. Preferably, the oxidation step (a) is performed at a pH between 5.0 and 6.0. In one embodiment, the oxidation step (a) is performed at a pH of about 5.0. After the oxidation step (a), the saccharides are considered activated and are referred to as "activated polysaccharides." In one embodiment, the activated serotype 23A polysaccharide of the present invention has a weight average molecular weight (Mw) between 50 kDa and 400 kDa. In another embodiment, the weight average molecular weight (Mw) is between 100 kDa and 250 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 120 kDa and 200 kDa. In one embodiment, the activated serotype 23A polysaccharide of the present invention retains at least 80% of branched rhamnose. In one embodiment, the activated serotype 23A polysaccharide of the present invention retains at least 85% of branched rhamnose. In one embodiment, the activated serotype 23A polysaccharide of the present invention retains at least 90% of branched rhamnose. In a preferred embodiment, the activated serotype 23A polysaccharide of the present invention retains at least 95% of branched rhamnose. In a preferred embodiment, the activated serotype 23A polysaccharide of the present invention retains at least 96% of the branched rhamnose. In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4- ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In a preferred embodiment, the oxidant is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In a most preferred embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.1 to 2 molar equivalents of periodate. Preferably, step a) comprises reacting the polysaccharide with 0.2 to 1.5 molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharide with 0.3 to 0.5 molar equivalents of periodate. In one embodiment, the degree of oxidation of the activated serotype 23A polysaccharide (also referred to herein as "activation degree") is between 2 and 20. In a preferred embodiment, the degree of oxidation of the activated serotype 23A polysaccharide is between 2 and 8. In the most preferred embodiment, the degree of oxidation of the activated serotype 23A polysaccharide is 5±2.5. In one embodiment, the activated serotype 23A polysaccharide and the carrier protein are lyophilized before step b). Lyophilization preferably occurs after step a). In one embodiment, the activated polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized. In one embodiment, the activated serotype 23A polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized, and the activated polysaccharide and the carrier protein are re-dissolved in the same solution. In one embodiment, the activated serotype 23A polysaccharide and the carrier protein are lyophilized separately (separate lyophilization). In one embodiment, the activated serotype 23A polysaccharide and the carrier protein are lyophilized together (co-lyophilization). In one embodiment, lyophilization occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, molasses, raffinose, stachyose, melezitose, polydextrose, mannitol, lactitol, and isomaltulose. In one embodiment, the sugar is selected from the group consisting of sucrose, molasses, and mannitol. In one embodiment, the sugar is sucrose, molasses, and mannitol. In one embodiment, the sugar is sucrose. In one embodiment, the initial input ratio (weight / weight) of activated serotype 23A capsular polysaccharide to carrier protein in step b) is between 2:1 and 0.5:1. In one embodiment, the initial input ratio (weight / weight) of activated serotype 23A capsular polysaccharide to carrier protein is between 1.2:1 and 0.6:1. The initial input ratio (weight / weight) of activated serotype 23A capsular polysaccharide to carrier protein is preferably between 0.9:1 and 0.7:1. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. Preferably, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulfoxide (DMSO) or dimethylformamide (DMF). The reduction reaction (c) is preferably carried out in the presence of dimethylsulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) or DMF (dimethylformamide) solvent. The reduction reaction (c) is best carried out in DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Burkholderia acid or a Lewis acid, an amine borane, such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of reducing agent are used in step c). Preferably, between 0.2 and 1.5 molar equivalents of reducing agent are used in step c). Optimally, between 0.5 and 1.0 molar equivalents of reducing agent are used in step c). At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH 4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation to the carrier protein, the serotype 23A glycoconjugate can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. Such techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Thus, in one embodiment, the process for producing the serotype 23A glycoconjugate of the present invention includes a step of purifying the glycoconjugate after production. 1.7 S. pneumoniae serotype 23B glycoconjugates of the present invention In one aspect, the present invention relates to glycoconjugates of Streptococcus pneumoniae serotype 23B. The structure of the S. pneumoniae serotype 23B polysaccharide is known in the art (see, for example, Ravenscroft N et al. (2017) Carbohydrate Res. Vol. 450, p 19-29 and WO2019050814). The structure of the serotype 23A capsular polysaccharide is: →4)-β-D-Glc p-(1→4)-[Gro-(2→P→3)]- β-D-Gal p-(1→4)-β-L-Rha p-(1→. In one embodiment, the capsular Streptococcus pneumoniae serotype 23B saccharide used in the present invention is a synthetic carbohydrate. However, in a preferred embodiment, the source of the bacterial polysaccharide according to the present invention can be Streptococcus pneumoniae serotype 23B bacterial cells. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 23B polysaccharide can be obtained from established culture collections (such as, for example, the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinical samples. Serotype 23B saccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art. They can also be obtained commercially (such as, for example, from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., Reference No. ATCC 548-X, No. ATCC 549-X, No. ATCC 550-X)). If serotype 23B sugar system is directly obtained from bacteria, bacterial cells can be grown in culture medium (preferably in a culture medium based on soybeans). After the bacterial cell fermentation of the production of Streptococcus pneumoniae serotype 23B capsular polysaccharide, the bacterial cells can be dissolved to produce cell lysates. Serotype 23B polysaccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, diafiltration and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752 and WO2020170190). Purified serotype 23B capsular polysaccharide can then be used to prepare glycoconjugates. Isolated serotype 23B capsular saccharides obtained by purifying serotype 23B polysaccharides from S. pneumoniae cell lysates and optionally size fractionating the purified polysaccharides can be characterized by various parameters including, for example, weight average molecular weight (Mw). The molecular weight of polysaccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In preferred embodiments, the isolated serotype 23B capsular polysaccharide (i.e., purified prior to further processing) has a weight average molecular weight between 100 kDa and 2500 kDa. In one embodiment, the isolated serotype 23B capsular polysaccharide has a weight average molecular weight between 250 kDa and 2000 kDa. In one embodiment, the isolated serotype 23B capsular polysaccharide has a weight average molecular weight between 300 kDa and 1000 kDa. Any integer within any of the above ranges is contemplated as an embodiment of the present disclosure. To produce serotype 23B conjugates with favorable filterability characteristics, immunogenicity, and / or yield, size fractionation of the polysaccharide to a target molecular weight range can be performed prior to conjugation to the carrier protein. It is desirable to reduce the size of the purified serotype 23B polysaccharide while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used. In one embodiment, the size of the purified serotype 23B polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis may be performed using a weak acid (e.g., acetic acid, formic acid, propionic acid). Chemical hydrolysis may also be performed using a diluted strong acid (e.g., diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitric acid, or diluted perchloric acid). However, the size of the purified serotype 23B polysaccharide can preferably be reduced by mechanical homogenization. In one embodiment, the size of the purified serotype 23B polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate is increased by using a higher applied homogenization pressure, and the exposure time can be increased by recirculating the feed stream through the homogenizer. In one embodiment, the isolated serotype 23B capsular polysaccharide is size-fractionated to a weight average molecular weight between 50 kDa and 750 kDa. In a preferred embodiment, the isolated serotype 23B capsular polysaccharide is size-fractionated to a weight average molecular weight between 75 kDa and 400 kDa. In an even more preferred embodiment, the isolated serotype 23B capsular polysaccharide is size-fractionated to a weight average molecular weight between 100 kDa and 250 kDa. The isolated serotype 23B polysaccharide is preferably size-fractionated by mechanical homogenization, most preferably by high pressure homogenization. In one embodiment, the isolated serotype 23B capsular polysaccharide is not size fractionated. In one embodiment, the isolated serotype 23B capsular polysaccharide has a weight average molecular weight of between 50 kDa and 750 kDa before conjugation. In one embodiment, the isolated serotype 23B capsular polysaccharide has a weight average molecular weight of between 75 kDa and 400 kDa before conjugation. In an even more preferred embodiment, the isolated serotype 23B capsular polysaccharide has a weight average molecular weight of between 100 kDa and 250 kDa before conjugation. The weight average molecular weight (Mw) of the saccharide prior to conjugation refers to the Mw of the polysaccharide prior to activation (i.e., after the final size fractionation step but before the polysaccharide is reacted with the activating agent). In the context of the present invention, the Mw of the 23B polysaccharide is not substantially modified by the activation step and the Mw of the 23B polysaccharide incorporated into the conjugate is similar to the Mw of the polysaccharide measured prior to activation. In one embodiment, the serotype 23B saccharide conjugates of the present invention comprise serotype 23B capsular polysaccharide, wherein the polysaccharide has a weight average molecular weight (Mw) of between 40 kDa and 600 kDa prior to conjugation. In another embodiment, the weight average molecular weight (Mw) is between 50 kDa and 300 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 100 kDa and 200 kDa. In some embodiments, the serotype 23B glycoconjugates of the present invention have a weight average molecular weight (Mw) between 250 kDa and 7,500 kDa. In other embodiments, the serotype 23B glycoconjugates have a weight average molecular weight (Mw) between 500 kDa and 4,000 kDa. Preferably, the serotype 23B glycoconjugates have a weight average molecular weight (Mw) between 700 kDa and 2,000 kDa. The serotype 23B glycoconjugates of the present invention can also be characterized by the sugar to carrier protein ratio (weight / weight). In some embodiments, the serotype 23B polysaccharide to carrier protein ratio (w / w) in the glycoconjugate is between 0.4 and 3.0. The sugar to carrier protein ratio (w / w) is preferably between 0.5 and 1.5. Even more preferably, the sugar to carrier protein ratio (w / w) is between 0.6 and 1.3. Another way to characterize the serotype 23B glycoconjugates of the present invention is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) to which the saccharide is bound. The saccharide can be characterized by the range of lysine residues bound (degree of binding). Evidence of lysine modification of the carrier protein due to covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Binding results in a reduction in the number of lysine residues recovered compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the degree of binding of the serotype 23B glycoconjugates of the present invention is between 2 and 15. Preferably, the degree of binding of the serotype 23B glycoconjugates of the present invention is between 5 and 12. The serotype 23B glycoconjugates and immunogenic compositions of the present invention may contain free sugars that are not covalently bound to a carrier protein but are still present in the glycoconjugate composition. The free sugars may be non-covalently associated with the glycoconjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or with the glycoconjugate). In one embodiment, the serotype 23B glycoconjugate comprises less than about 40% free serotype 23B polysaccharide compared to the total amount of serotype 23B polysaccharide. In a preferred embodiment, the serotype 23B glycoconjugate comprises less than about 25% free serotype 23B polysaccharide compared to the total amount of serotype 23B polysaccharide. Serotype 23B glycoconjugates can also be characterized by their molecular size distribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relative molecular size distribution of conjugates. Size exclusion chromatography (SEC) is used in gravity-fed columns to determine the molecular size distribution profile of the conjugates. Large molecules, excluded from the pores in the media, elute faster than small molecules. The column eluate is collected using a fraction collector. The fractions are colorimetrically tested using a sugar assay. The column used for Kd determination is calibrated to establish the fraction (V0) of molecules that are completely excluded (Kd = 0) and the fraction (Vi) representing maximum retention (Kd = 1). The fraction (Ve) that achieves a specific sample attribute is related to the Kd using the equation Kd = (Ve - V0) / (Vi - V0). In one embodiment, at least 30% of the serotype 23B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 35% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 40% and 60% of the serotype 23B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, the serotype 23B sugar is activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate. The activated sugar can then be linked directly or via a spacer (linker) group to a carrier protein (preferably CRM). 197 ). For example, the spacer may be cystamine or cysteamine, which gives a thiolated polysaccharide that can be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl)aminobenzoate (S1AB), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfoSIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino]propionate (SBAP)). Cyanate esters are preferably coupled with hexamethylenediamine or adipic acid dihydrazide (ADH), and amine-derivatized sugars are coupled to carrier proteins (e.g., CRMs) via carboxyl groups on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. 197 Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348 and WO 96 / 129094. Other suitable techniques for conjugation include the use of carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, and TSTU. Many of these techniques are described in International Patent Application Publication No. WO 98 / 42721. Conjugation can involve a carbonyl linker, which can be formed by reacting the free hydroxyl groups of the sugar with 1,1'-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with the protein to form a carbamate linkage. This can involve reducing the mutarotomer terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amine group on the protein. In a preferred embodiment, the serotype 23B glycoconjugates of the present invention are prepared using reductive amination chemistry. According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of the purified saccharide, and (2) reduction of the activated saccharide and carrier protein to form the glycoconjugate (see, e.g., WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, the serotype 23B glycoconjugate of the present invention is prepared by conjugating isolated serotype 23B capsular polysaccharide to a carrier protein in a process comprising the following steps: (a) reacting the isolated serotype 23B capsular polysaccharide with an oxidizing agent; (b) complexing the activated polysaccharide of step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As described above, size fractionation of the isolated serotype 23B capsular polysaccharide to a target molecular weight (MW) range may be performed prior to oxidation. Thus, in one embodiment, the isolated serotype 23B capsular polysaccharide is size fractionated prior to oxidation. In a preferred embodiment, the size of the isolated serotype 23B capsular polysaccharide can be reduced by mechanical homogenization. In one embodiment, the size of the isolated serotype 23B polysaccharide is reduced by high pressure homogenization. In one embodiment, the isolated serotype 23B capsular polysaccharide is not size fractionated prior to oxidation. In one embodiment, the oxidation step (a) is performed at a pH between 4.0 and 6.5. Preferably, the oxidation step (a) is performed at a pH between 4.5 and 5.5. In one embodiment, the oxidation step (a) is performed at a pH of about 5.0. After the oxidation step (a), the sugars are considered activated and are referred to as "activated polysaccharides." In one embodiment, the activated serotype 23B polysaccharide of the present invention has a weight average molecular weight (Mw) between 40 kDa and 600 kDa. In another embodiment, the weight average molecular weight (Mw) is between 50 kDa and 300 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 100 kDa and 200 kDa. In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4- ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In a preferred embodiment, the oxidant is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In a most preferred embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.05 to 1 molar equivalent of periodate. Preferably, step a) comprises reacting the polysaccharide with 0.1 to 0.3 molar equivalent of periodate. Most preferably, step a) comprises reacting the polysaccharide with about 0.2 molar equivalent of periodate. In one embodiment, the degree of oxidation of the activated serotype 23B polysaccharide (also referred to herein as "activation degree") is between 2 and 20. In a preferred embodiment, the degree of oxidation of the activated serotype 23B polysaccharide is between 4 and 15. In the most preferred embodiment, the degree of oxidation of the activated serotype 23B polysaccharide is 9±3. In one embodiment, the activated serotype 23B polysaccharide and the carrier protein are lyophilized before step b). Lyophilization preferably occurs after step a). In one embodiment, the activated polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized. In one embodiment, the activated serotype 23B polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized, and the activated polysaccharide and the carrier protein are re-dissolved in the same solution. In one embodiment, the activated serotype 23B polysaccharide and the carrier protein are lyophilized separately (separate lyophilization). In one embodiment, the activated serotype 23B polysaccharide and the carrier protein are lyophilized together (co-lyophilization). In one embodiment, lyophilization occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, molasses, raffinose, stachyose, melezitose, polydextrose, mannitol, lactitol, and isomaltulose. In one embodiment, the sugar is selected from the group consisting of sucrose, molasses, and mannitol. In one embodiment, the sugar is sucrose, molasses, or mannitol. In one embodiment, the sugar is sucrose. In one embodiment, the initial input ratio (weight / weight) of activated serotype 23B capsular polysaccharide to carrier protein in step b) is between 2:1 and 0.5:1. In one embodiment, the initial input ratio (weight / weight) of activated serotype 23B capsular polysaccharide to carrier protein is between 1.2:1 and 0.6:1. The initial input ratio (weight / weight) of activated serotype 23B capsular polysaccharide to carrier protein is preferably between 0.9:1 and 0.7:1. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. Preferably, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulfoxide (DMSO) or dimethylformamide (DMF). The reduction reaction (c) is preferably carried out in the presence of dimethylsulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) or DMF (dimethylformamide) solvent. The reduction reaction (c) is best carried out in DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Burkholderia acid or a Lewis acid, an amine borane, such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of reducing agent are used in step c). Preferably, between 0.5 and 1.5 molar equivalents of reducing agent are used in step c). Optimally, between 0.9 and 1.1 molar equivalents of reducing agent are used in step c). At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH 4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation to the carrier protein, the serotype 23B glycoconjugate can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. Such techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Thus, in one embodiment, the process for producing the serotype 23B glycoconjugate of the present invention includes a step of purifying the glycoconjugate after production. 1.8 S. pneumoniae serotype 24F glycoconjugate of the present invention In one aspect, the present invention relates to glycoconjugates of S. pneumoniae serotype 24F. The structure of S. pneumoniae serotype 24F polysaccharide is known in the art (see, for example, WO2019050815). In one embodiment, the S. pneumoniae serotype 24F saccharide used in the present invention is a synthetic carbohydrate. However, in a preferred embodiment, the source of the bacterial polysaccharide according to the present invention can be Streptococcus pneumoniae serotype 24F bacterial cells. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 24F polysaccharide can be obtained from established culture collections (such as, for example, the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinical samples. Serotype 24F saccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art. They can also be purchased commercially (such as, for example, from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., Reference No. ATCC 551-X, No. ATCC 552-X, No. ATCC 553-X)). If the serotype 24F saccharide is directly obtained from bacteria, the bacterial cells can be grown in a culture medium (preferably in a soy-based culture medium). After the bacterial cells producing the S. pneumoniae serotype 24F capsular polysaccharide are fermented, the bacterial cells can be dissolved to produce a cell lysate. The serotype 24F polysaccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, deep filtration, precipitation, ultrafiltration, treatment with activated carbon, diafiltration and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 24F capsular polysaccharide can then be used to prepare glycoconjugates. Isolated serotype 24F capsular saccharides obtained by purifying serotype 24F polysaccharides from S. pneumoniae cell lysates and optionally size fractionating the purified polysaccharides can be characterized by various parameters including, for example, weight average molecular weight (Mw). The molecular weight of polysaccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In preferred embodiments, the isolated serotype 24F capsular polysaccharide (i.e., purified prior to further processing) has a weight average molecular weight between 100 kDa and 2500 kDa. In one embodiment, the isolated serotype 24F capsular polysaccharide has a weight average molecular weight between 250 kDa and 2000 kDa. In one embodiment, the isolated serotype 24F capsular polysaccharide has a weight average molecular weight between 500 kDa and 1000 kDa. Any integer within any of the above ranges is contemplated as an embodiment of the present disclosure. To produce serotype 24F conjugates with favorable filterability characteristics, immunogenicity, and / or yield, size fractionation of the polysaccharide to a target molecular weight range can be performed prior to conjugation to the carrier protein. It is desirable to reduce the size of the purified serotype 24F polysaccharide while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used. The size of purified serotype 24F polysaccharide can be optimally reduced by mechanical homogenization. It has not been found suitable to use acid hydrolysis to reduce the size of serotype 24F polysaccharide, as suggested in WO2019050815 or WO2019050818. Acid hydrolysis has been found to affect the structural integrity of the serotype 24F polysaccharide. It has been found that even relatively mild hydrolysis (e.g., treatment with 100 mM acetic acid at 80°C for approximately 2 hours) results in a loss of 25% of the branched ribose residues (see Figure 2). Mechanical size fractionation does not release this residue, which may be important from an immunological point of view. Therefore, in a preferred embodiment, the size of the purified serotype 24F polysaccharide can be reduced by mechanical homogenization. In one embodiment, the size of the purified serotype 24F polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate is increased by using a higher applied homogenization pressure, and the exposure time can be increased by recirculating the feed stream through the homogenizer. In a preferred embodiment, the process for preparing the serotype 24F glycoconjugates of the present invention does not include a size fractionation step of the serotype 24F polysaccharide by acid hydrolysis. In one embodiment, the isolated serotype 24F capsular polysaccharide is size-fractionated to a weight average molecular weight between 50 kDa and 500 kDa. In a preferred embodiment, the isolated serotype 24F capsular polysaccharide is size-fractionated to a weight average molecular weight between 75 kDa and 400 kDa. In an even more preferred embodiment, the isolated serotype 24F capsular polysaccharide is size-fractionated to a weight average molecular weight between 125 kDa and 275 kDa. In a most preferred embodiment, the isolated serotype 24F capsular polysaccharide is size-fractionated to a weight average molecular weight between 125 kDa and 225 kDa. The isolated serotype 24F polysaccharide is preferably size-fractionated by mechanical homogenization, most preferably by high-pressure homogenization. In one embodiment, the isolated serotype 24F capsular polysaccharide is not size fractionated. In one embodiment, the isolated serotype 24F capsular polysaccharide has a weight average molecular weight of between 50 kDa and 500 kDa before conjugation. In one embodiment, the isolated serotype 24F capsular polysaccharide has a weight average molecular weight of between 75 kDa and 400 kDa before conjugation. In an even more preferred embodiment, the isolated serotype 24F capsular polysaccharide has a weight average molecular weight of between 125 kDa and 275 kDa before conjugation. In a most preferred embodiment, the isolated serotype 24F capsular polysaccharide has a weight average molecular weight of between 125 kDa and 225 kDa before conjugation. The weight average molecular weight (Mw) of the saccharide prior to conjugation refers to the Mw of the polysaccharide prior to activation (i.e., after the final size fractionation step but before the polysaccharide is reacted with the activating agent). In the context of the present invention, the Mw of the 24F polysaccharide is not substantially modified by the activation step, and the Mw of the 24F polysaccharide incorporated into the conjugate is similar to the Mw of the polysaccharide measured prior to activation. In one embodiment, the serotype 24F saccharide conjugates of the present invention comprise serotype 24F capsular polysaccharide, wherein the polysaccharide has a weight average molecular weight (Mw) of between 50 kDa and 400 kDa prior to conjugation. In another embodiment, the weight average molecular weight (Mw) is between 120 kDa and 250 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 120 kDa and 200 kDa. In some embodiments, the serotype 24F glycoconjugates of the present invention have a weight average molecular weight (Mw) between 500 kDa and 10,000 kDa. In other embodiments, the serotype 24F glycoconjugates have a weight average molecular weight (Mw) between 1,500 kDa and 7,500 kDa. Preferably, the serotype 24F glycoconjugates have a weight average molecular weight (Mw) between 3,000 kDa and 6,000 kDa. The serotype 24F glycoconjugates of the present invention can also be characterized by the sugar to carrier protein ratio (weight / weight). In some embodiments, the serotype 24F polysaccharide to carrier protein ratio (w / w) in the glycoconjugate is between 0.5 and 3.0. The sugar to carrier protein ratio (w / w) is preferably between 0.7 and 1.5. Even more preferably, the sugar to carrier protein ratio (w / w) is between 0.8 and 1.4. Another way to characterize the serotype 24F glycoconjugates of the present invention is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) to which the saccharide is bound. The saccharide can be characterized by the range of bound lysine residues (degree of binding). Evidence of lysine modification of the carrier protein due to covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Binding results in a reduction in the number of recovered lysine residues compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the degree of binding of the serotype 24F glycoconjugates of the present invention is between 2 and 15. Preferably, the degree of binding of the serotype 24F glycoconjugates of the present invention is between 5 and 12. The serotype 24F glycoconjugates and immunogenic compositions of the present invention may contain free sugars that are not covalently bound to a carrier protein but are still present in the glycoconjugate composition. The free sugars may be non-covalently associated with the glycoconjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or with the glycoconjugate). In one embodiment, the serotype 24F glycoconjugate comprises less than about 40% free serotype 24F polysaccharide compared to the total amount of serotype 24F polysaccharide. In a preferred embodiment, the serotype 24F glycoconjugate comprises less than about 25% free serotype 24F polysaccharide compared to the total amount of serotype 24F polysaccharide. Serotype 24F glycoconjugates can also be characterized by their molecular size distribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relative molecular size distribution of conjugates. Size exclusion chromatography (SEC) is used in a gravity-fed column to determine the molecular size distribution profile of the conjugate. Large molecules, excluded from the pores in the media, elute faster than small molecules. The column eluate is collected using a fraction collector. The fractions are colorimetrically analyzed using a sugar assay. The column used for Kd determination is calibrated to establish the fraction (V0) of molecules that are completely excluded (Kd = 0) and the fraction (Vi) representing maximum retention (Kd = 1). The fraction (Ve) that achieves a specific sample attribute is related to the Kd using the equation Kd = (Ve - V0) / (Vi - V0). In one embodiment, at least 40% of the serotype 24F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a more preferred embodiment, between 50% and 90% of the serotype 24F glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. Serotype 24F glycoconjugates can also be characterized by the amount of branched ribose residues remaining in the 24F polysaccharide. As mentioned above, serotype 24F polysaccharide has been found to release branched ribose residues (see Figure 7). Thus, in one embodiment, the S. pneumoniae serotype 24F glycoconjugates of the present invention comprise S. pneumoniae serotype 24F capsular polysaccharide wherein the S. pneumoniae serotype 24F capsular polysaccharide has a ribose content of greater than 75% when compared to a native S. pneumoniae serotype 24F capsular polysaccharide wherein the ribose content is considered to be about 100%. In one embodiment, the S. pneumoniae serotype 24F glycoconjugates of the present invention comprise S. pneumoniae serotype 24F capsular polysaccharide wherein the S. pneumoniae serotype 24F capsular polysaccharide has a ribose content of greater than 90% when compared to a native S. pneumoniae serotype 24F capsular polysaccharide wherein the ribose content is considered to be about 100%. The S. pneumoniae serotype 24F glycoconjugates of the present invention preferably comprise S. pneumoniae serotype 24F capsular polysaccharide wherein the S. pneumoniae serotype 24F capsular polysaccharide has a ribose content greater than 95% when compared to native S. pneumoniae serotype 24F capsular polysaccharide wherein the ribose content is considered to be about 100%. In a preferred embodiment, the S. pneumoniae serotype 24F glycoconjugates of the present invention comprise S. pneumoniae serotype 24F capsular polysaccharide wherein the S. pneumoniae serotype 24F capsular polysaccharide has a ribose content of about 100% when compared to native S. pneumoniae serotype 24F capsular polysaccharide wherein the ribose content is considered to be about 100%. In one embodiment, the serotype 24F saccharide is activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate. The activated saccharide can then be directly or through a spacer (linker) group to a carrier protein (preferably CRM). 197 ). For example, the spacer may be cystamine or cysteamine, which gives a thiolated polysaccharide that can be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl)aminobenzoate (S1AB), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfoSIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino]propionate (SBAP)). Cyanate esters are preferably coupled with hexamethylenediamine or adipic acid dihydrazide (ADH), and amine-derivatized sugars are coupled to carrier proteins (e.g., CRMs) via carboxyl groups on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. 197 Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348 and WO 96 / 129094. Other suitable techniques for conjugation include the use of carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, and TSTU. Many of these techniques are described in International Patent Application Publication No. WO 98 / 42721. Conjugation can involve a carbonyl linker, which can be formed by reacting the free hydroxyl groups of the sugar with 1,1'-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with the protein to form a carbamate linkage. This can involve reducing the mutarotomer terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amine group on the protein. In a preferred embodiment, the serotype 24F glycoconjugates of the present invention are prepared using reductive amination chemistry. According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of the purified saccharide, and (2) reduction of the activated saccharide and carrier protein to form the glycoconjugate. In one embodiment, the serotype 24F glycoconjugate of the present invention is prepared by conjugating isolated serotype 24F capsular polysaccharide to a carrier protein using a process comprising the following steps: (a) reacting the isolated serotype 24F capsular polysaccharide with an oxidizing agent; (b) complexing the activated polysaccharide from step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As described above, size fractionation of the isolated serotype 24F capsular polysaccharide to a target molecular weight (MW) range may be performed prior to oxidation. Thus, in one embodiment, the isolated serotype 24F capsular polysaccharide is size fractionated prior to oxidation. In a preferred embodiment, the size of the isolated serotype 24F capsular polysaccharide can be reduced by mechanical homogenization. In one embodiment, the size of the isolated serotype 24F polysaccharide is reduced by high pressure homogenization. In a most preferred embodiment, the isolated serotype 24F capsular polysaccharide is not size-fractionated by acid hydrolysis. In one embodiment, the isolated serotype 24F capsular polysaccharide is not size fractionated prior to oxidation. In one embodiment, the oxidation step (a) is performed at a pH between 4.5 and 6.5. Preferably, the oxidation step (a) is performed at a pH between 5.0 and 6.0. In one embodiment, the oxidation step (a) is performed at a pH of about 5.0. After the oxidation step (a), the saccharides are considered activated and are referred to as "activated polysaccharides." In one embodiment, the activated serotype 24F polysaccharide of the present invention has a weight average molecular weight (Mw) between 50 kDa and 400 kDa. In another embodiment, the weight average molecular weight (Mw) is between 120 kDa and 250 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 120 kDa and 200 kDa. In one embodiment, the activated serotype 24F polysaccharide of the present invention retains at least 75% of the branched ribose. In one embodiment, the activated serotype 24F polysaccharide of the present invention retains at least 90% of the branched ribose. In a preferred embodiment, the activated serotype 24F polysaccharide of the present invention retains at least 95% of the branched ribose. In the best embodiment, the activated serotype 24F polysaccharide of the present invention retains about 100% of the branched ribose. In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4- ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In a preferred embodiment, the oxidant is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In a most preferred embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.1 to 2 molar equivalents of periodate. Preferably, step a) comprises reacting the polysaccharide with 0.5 to 1.5 molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharide with 0.9 to 1.1 molar equivalents of periodate. In one embodiment, the degree of oxidation of the activated serotype 24F polysaccharide (also referred to herein as "activation degree") is between 2 and 20. In a preferred embodiment, the degree of oxidation of the activated serotype 24F polysaccharide is between 4 and 15. In the most preferred embodiment, the degree of oxidation of the activated serotype 24F polysaccharide is 9±3. In one embodiment, the activated serotype 24F polysaccharide and the carrier protein are lyophilized before step b). Lyophilization preferably occurs after step a). In one embodiment, the activated polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized. In one embodiment, the activated serotype 24F polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized, and the activated polysaccharide and the carrier protein are re-dissolved in the same solution. In one embodiment, the activated serotype 24F polysaccharide and the carrier protein are lyophilized separately (separate lyophilization). In one embodiment, the activated serotype 24F polysaccharide and the carrier protein are lyophilized together (co-lyophilization). In one embodiment, lyophilization occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, molasses, raffinose, stachyose, melezitose, polydextrose, mannitol, lactitol, and isomaltulose. In one embodiment, the sugar is selected from the group consisting of sucrose, molasses, and mannitol. In one embodiment, the sugar is sucrose, molasses, or mannitol. In one embodiment, the sugar is sucrose. In one embodiment, the initial input ratio (weight / weight) of activated serotype 24F capsular polysaccharide to carrier protein in step b) is between 2:1 and 0.5:1. In one embodiment, the initial input ratio (weight / weight) of activated serotype 24F capsular polysaccharide to carrier protein is between 1.2:1 and 0.6:1. The initial input ratio (weight / weight) of activated serotype 24F capsular polysaccharide to carrier protein is preferably between 0.9:1 and 0.7:1. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. Preferably, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulfoxide (DMSO) or dimethylformamide (DMF). The reduction reaction (c) is preferably carried out in the presence of dimethylsulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) or DMF (dimethylformamide) solvent. The reduction reaction (c) is best carried out in DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Burkholderia acid or a Lewis acid, an amine borane, such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of reducing agent are used in step c). Preferably, between 0.5 and 2.5 molar equivalents of reducing agent are used in step c). Optimally, between 1.5 and 2.5 molar equivalents of reducing agent are used in step c). In one embodiment, about 2 molar equivalents of the reducing agent are used in step c). At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH 4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 3 molar equivalents of sodium borohydride. In one embodiment, capping is achieved by mixing the product of step c) with about 2 molar equivalents of sodium borohydride. After conjugation to the carrier protein, the serotype 24F glycoconjugate can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. Such techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Thus, in one embodiment, the process for producing the serotype 24F glycoconjugate of the present invention includes a step of purifying the glycoconjugate after production. 1.9 S. pneumoniae serotype 35B glycoconjugates of the present invention In one aspect, the present invention relates to glycoconjugates of Streptococcus pneumoniae serotype 35B. The structure of the S. pneumoniae serotype 35B polysaccharide is known in the art (see, eg, Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899). In one embodiment, the S. pneumoniae serotype 35B saccharide used in the present invention is a synthetic carbohydrate. However, in a preferred embodiment, the source of the bacterial polysaccharide according to the present invention can be Streptococcus pneumoniae serotype 35B bacterial cells. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 35B polysaccharide can be obtained from established culture collections (such as, for example, the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinical samples. Serotype 35B saccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art. They can also be obtained commercially (such as, for example, from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., Reference No. ATCC 539-X, No. ATCC 540-X, No. ATCC 541-X)). If the serotype 35B saccharide is directly obtained from bacteria, the bacterial cells can be grown in a culture medium (preferably in a culture medium based on soybeans). After the bacterial cells producing the pneumococcal serotype 35B capsular polysaccharide are fermented, the bacterial cells can be dissolved to produce cell lysates. The serotype 35B polysaccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, diafiltration and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 35B capsular polysaccharide can then be used to prepare glycoconjugates. Isolated serotype 35B capsular saccharides obtained by purifying serotype 35B polysaccharides from S. pneumoniae cell lysates and optionally size fractionating the purified polysaccharides can be characterized by various parameters including, for example, weight average molecular weight (Mw). The molecular weight of polysaccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In preferred embodiments, the isolated serotype 35B capsular polysaccharide (i.e., purified prior to further processing) has a weight average molecular weight between 100 kDa and 5000 kDa. In one embodiment, the isolated serotype 35B capsular polysaccharide has a weight average molecular weight between 300 kDa and 2000 kDa. In a further preferred embodiment, the isolated serotype 35B capsular polysaccharide has a weight average molecular weight between 500 kDa and 1000 kDa. Any integer within any of the above ranges is contemplated as an embodiment of the present disclosure. Purified serotype 35B polysaccharides can be reduced in size while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used. However, it has been found that S. pneumoniae serotype 35B polysaccharide fragments during activation with periodate, a classic oxidizing agent used in common reductive amination processes. Periodate oxidation appears to occur within the backbone of the serotype 35B polysaccharide and cleaves mannitol or ribitol, resulting in size reduction. Activation with periodate results in a decrease in the polysaccharide Mw. Therefore, in the examples where periodate activation was used, serotype 35B capsular polysaccharide was not size-fractionated. Thus, in one embodiment, the isolated serotype 35B capsular polysaccharide is not size fractionated. In one embodiment, the isolated serotype 35B capsular polysaccharide has a weight average molecular weight of between 100 kDa and 5,000 kDa before conjugation. In one embodiment, the isolated serotype 35B capsular polysaccharide has a weight average molecular weight of between 300 kDa and 2000 kDa before conjugation. In an even more preferred embodiment, the isolated serotype 35B capsular polysaccharide has a weight average molecular weight of between 500 kDa and 1000 kDa before conjugation. The weight average molecular weight (Mw) of the saccharide before conjugation refers to the Mw of the polysaccharide before activation (ie, before the polysaccharide reacts with the activating agent). In one embodiment, the serotype 35B saccharide conjugates of the present invention comprise serotype 35B capsular polysaccharide, wherein the polysaccharide has a weight average molecular weight (Mw) between 15 kDa and 100 kDa. In another embodiment, the weight average molecular weight (Mw) is between 25 kDa and 50 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between about 30 kDa and about 40 kDa. In some embodiments, the serotype 35B glycoconjugates of the present invention have a weight average molecular weight (Mw) between 250 kDa and 7,500 kDa. In other embodiments, the serotype 35B glycoconjugates have a weight average molecular weight (Mw) between 500 kDa and 5,000 kDa. Preferably, the serotype 35B glycoconjugates have a weight average molecular weight (Mw) between 1,000 kDa and 4,000 kDa. The serotype 35B glycoconjugates of the present invention can also be characterized by the sugar to carrier protein ratio (weight / weight). In some embodiments, the serotype 35B polysaccharide to carrier protein ratio (w / w) in the glycoconjugate is between 0.4 and 3.0. The sugar to carrier protein ratio (w / w) is preferably between 0.4 and 2.0. Even more preferably, the sugar to carrier protein ratio (w / w) is between 0.5 and 1.5. Another way to characterize the serotype 35B glycoconjugates of the present invention is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) to which the saccharide is bound. The saccharide can be characterized by the range of bound lysine residues (degree of binding). Evidence of lysine modification of the carrier protein due to covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Binding results in a reduction in the number of recovered lysine residues compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the degree of binding of the serotype 35B glycoconjugates of the present invention is between 2 and 15. Preferably, the degree of binding of the serotype 35B glycoconjugates of the present invention is between 5 and 10. The serotype 35B glycoconjugates and immunogenic compositions of the present invention may contain free saccharides that are not covalently bound to a carrier protein but are still present in the glycoconjugate composition. The free saccharides may be non-covalently associated with the glycoconjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or with the glycoconjugate). In one embodiment, the serotype 35B glycoconjugate comprises less than about 40% free serotype 35B polysaccharide, compared to the total amount of serotype 35B polysaccharide. In one embodiment, the serotype 35B glycoconjugate comprises less than about 20% free serotype 35B polysaccharide, compared to the total amount of serotype 35B polysaccharide. In a preferred embodiment, the serotype 35B glycoconjugate comprises less than about 10% free serotype 35B polysaccharide, compared to the total amount of serotype 35B polysaccharide. Serotype 35B glycoconjugates can also be characterized by their molecular size distribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relative molecular size distribution of conjugates. Size exclusion chromatography (SEC) is used in gravity-fed columns to determine the molecular size distribution profile of the conjugates. Large molecules, excluded from the pores in the media, elute faster than small molecules. The column eluate is collected using a fraction collector. The fractions are colorimetrically tested using a sugar assay. The column used for Kd determination is calibrated to establish the fraction (V0) of molecules that are completely excluded (Kd = 0) and the fraction (Vi) representing maximum retention (Kd = 1). The fraction (Ve) that achieves a specific sample attribute is related to the Kd using the equation Kd = (Ve - V0) / (Vi - V0). In one embodiment, at least 40% of the serotype 35B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In a preferred embodiment, at least 60% of the serotype 35B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In an even more preferred embodiment, between 50% and 80% of the serotype 35B glycoconjugates have a Kd of less than or equal to 0.3 on a CL-4B column. In one embodiment, serotype 35B saccharides are activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form cyanate. The activated saccharide can then be linked directly or via a spacer (linker) group to a carrier protein (preferably CRM). 197 ). For example, the spacer may be cystamine or cysteamine, which gives a thiolated polysaccharide that can be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl)aminobenzoate (S1AB), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfoSIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino]propionate (SBAP)). Cyanate esters are preferably coupled with hexamethylenediamine or adipic acid dihydrazide (ADH), and amine-derivatized sugars are coupled to carrier proteins (e.g., CRMs) via carboxyl groups on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. 197 Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348 and WO 96 / 129094. Other suitable techniques for conjugation include the use of carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, and TSTU. Many of these techniques are described in International Patent Application Publication No. WO 98 / 42721. Conjugation can involve a carbonyl linker, which can be formed by reacting the free hydroxyl groups of the sugar with 1,1'-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with the protein to form a carbamate linkage. This can involve reducing the mutarotomer terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amine group on the protein. In a preferred embodiment, the serotype 35B glycoconjugates of the present invention are prepared using reductive amination chemistry. According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of the purified saccharide, and (2) reduction of the activated saccharide and carrier protein to form the glycoconjugate. In one embodiment, the serotype 35B glycoconjugate of the present invention is prepared by conjugating isolated serotype 35B capsular polysaccharide to a carrier protein in a process comprising the following steps: (a) reacting the isolated serotype 35B capsular polysaccharide with an oxidizing agent; (b) complexing the activated polysaccharide from step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. The isolated serotype 35B capsular polysaccharide is preferably not size fractionated prior to oxidation. In a preferred embodiment, step (a) is performed by adding a quenching agent to terminate the oxidation. Therefore, in a preferred embodiment, the serotype 35B saccharide conjugate of the present invention is prepared by conjugating isolated serotype 35B capsular polysaccharide to a carrier protein using a process comprising the following steps: (a) reacting the isolated serotype 35B capsular polysaccharide with an oxidizing agent; (a') quenching the oxidation reaction by adding a quenching agent to obtain activated serotype 35B capsular polysaccharide; (b) complexing the activated saccharide from step (a') with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a saccharide conjugate. In one embodiment, the oxidation step (a) is performed at a pH between 5.0 and 7.0. Preferably, the oxidation step (a) is performed at a pH between 5.5 and 6.5. In one embodiment, the oxidation step (a) is performed at a pH of about 6.0. After oxidation steps (a) to (a'), the saccharides are considered activated and are referred to as "activated polysaccharides." In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4- ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In a preferred embodiment, the oxidant is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In a most preferred embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.05 to 0.2 molar equivalents of periodate. Preferably, step a) comprises reacting the polysaccharide with 0.09 to 0.11 molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharide with about 0.1 molar equivalents of periodate. In one embodiment, the quencher is selected from a vicinal diol, a 1,2-amino alcohol, an amino acid, glutathione, a sulfite, a bisulfate, a dithiosulfinate, a metabisulfite, a thiosulfate, a phosphite, a hypophosphite, or a phosphorous acid. In one embodiment, the quencher is a 1,2-amino alcohol of formula (I): where R 1 is selected from H, methyl, ethyl, propyl or isopropyl. In one embodiment, the quencher is selected from sodium and potassium salts of sulfites, bisulfates, dithiosulfinates, metabisulfites, thiosulfates, phosphites, hypophosphites, or phosphorous acids. In one embodiment, the quencher is an amino acid. In these embodiments, the amino acid can be selected from serine, threonine, cysteine, cystine, methionine, proline, hydroxyproline, tryptophan, tyrosine, and histidine. In one embodiment, the quencher is a sulfite, such as bisulfate, dithiosulfinate, metabisulfite, or thiosulfate. In one embodiment, the quencher is a compound comprising two vicinal hydroxyl groups (vicinal diol), ie, comprising two hydroxyl groups covalently bonded to two adjacent carbon atoms. The quencher is preferably a compound of formula (II): where R 1 and R 2 Each is independently selected from H, methyl, ethyl, propyl or isopropyl. In a preferred embodiment, the quencher is glycerol, ethylene glycol, 1,2-propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, or ascorbic acid. In the best embodiment, the quencher is 2,3-butylene glycol. In a preferred embodiment, the isolated serotype 35B polysaccharide is activated by a process comprising the following steps: (a) reacting the isolated serotype 35B polysaccharide with periodate; (b) quenching the oxidation reaction by adding 2,3-butanediol to obtain activated serotype 35B polysaccharide. Following the oxidation step of the polysaccharide, the polysaccharide is considered activated and is hereinafter referred to as "activated polysaccharide." In one embodiment, the activated serotype 35B polysaccharide of the present invention has a weight average molecular weight (Mw) between 15 kDa and 100 kDa. In another embodiment, the weight average molecular weight (Mw) is between 25 kDa and 50 kDa. In a most preferred embodiment, the weight average molecular weight (Mw) is between 30 kDa and 40 kDa. In one embodiment, the degree of oxidation of the activated serotype 35B polysaccharide (also referred to herein as "activation degree") is between 2 and 20. In a preferred embodiment, the degree of oxidation of the activated serotype 35B polysaccharide is between 4 and 15. In the most preferred embodiment, the degree of oxidation of the activated serotype 35B polysaccharide is 9±3. In one embodiment, the activated serotype 35B polysaccharide and the carrier protein are lyophilized before step b). Lyophilization preferably occurs after step a). In one embodiment, the activated polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized. In one embodiment, the activated serotype 35B polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized, and the activated polysaccharide and the carrier protein are re-dissolved in the same solution. In one embodiment, the activated serotype 35B polysaccharide and the carrier protein are lyophilized separately (separate lyophilization). In one embodiment, the activated serotype 35B polysaccharide and the carrier protein are lyophilized together (co-lyophilization). In one embodiment, lyophilization occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, molasses, raffinose, stachyose, melezitose, polydextrose, mannitol, lactitol, and isomaltulose. In one embodiment, the sugar is selected from the group consisting of sucrose, molasses, and mannitol. In one embodiment, the sugar is sucrose, molasses, or mannitol. In one embodiment, the sugar is sucrose. In one embodiment, the initial input ratio (weight / weight) of activated serotype 35B capsular polysaccharide to carrier protein in step b) is between 2:1 and 0.5:1. In one embodiment, the initial input ratio (weight / weight) of activated serotype 35B capsular polysaccharide to carrier protein is between 1.2:1 and 0.6:1. The initial input ratio (weight / weight) of activated serotype 35B capsular polysaccharide to carrier protein is preferably between 0.9:1 and 0.7:1. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. Preferably, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulfoxide (DMSO) or dimethylformamide (DMF). The reduction reaction (c) is preferably carried out in the presence of dimethylsulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) or DMF (dimethylformamide) solvent. The reduction reaction (c) is best carried out in DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Burkholderia acid or a Lewis acid, an amine borane, such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of reducing agent are used in step c). Preferably, between 0.5 and 1.5 molar equivalents of reducing agent are used in step c). Optimally, between 0.9 and 1.1 molar equivalents of reducing agent are used in step c). At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH 4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation to the carrier protein, the serotype 35B glycoconjugate can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. Such techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Thus, in one embodiment, the process for producing the serotype 35B glycoconjugate of the present invention includes a step of purifying the glycoconjugate after production. 1.10 S. pneumoniae serotype 3 glycoconjugates of the present invention In one aspect, the present invention relates to a composition comprising a serotype 3 glycoconjugate of Streptococcus pneumoniae. The structure of the polysaccharide of Streptococcus pneumoniae serotype 3 is known in the art. The repeating unit of the polysaccharide of serotype 3 is composed of a glucopyranose (Glc p) and a glucuronic acid (Glc The glycosylated oligosaccharide is composed of linear disaccharide units of pA) (see, for example, Geno K et al. (2015) Clin Microbiol Rev Vol 28: 3, p 871-899). In one embodiment, the capsular S. pneumoniae serotype 3 saccharide used in the present invention is a synthetic carbohydrate. Synthetic S. pneumoniae type 3 capsular saccharide can be prepared, for example, as disclosed in WO2017178664 or WO2015040140. However, in a preferred embodiment, the source of the bacterial polysaccharide according to the present invention can be Streptococcus pneumoniae serotype 3 bacterial cells. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 3 polysaccharide can be obtained from established culture collections (such as, for example, from the Streptococcus Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinical samples. Serotype 3 polysaccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art (see, for example, the methods disclosed in US2006 / 0228380, US2006 / 0228381, US2007 / 0184071, US2007 / 0184072, US2007 / 0231340, and US2008 / 0102498, and WO2008 / 118752). Serotype 3 polysaccharides can also be produced using synthetic methods known to those skilled in the art. They are also commercially available (such as, for example, from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., reference numbers ATCC 172-X or ATCC 33-X). If the serotype 3 polysaccharide is obtained directly from bacteria, the bacterial cells can be grown in a culture medium (preferably a soy-based culture medium). After fermentation of the bacterial cells producing the S. pneumoniae serotype 3 capsular polysaccharide, the bacterial cells can be lysed to produce a cell lysate. The serotype 3 polysaccharide can then be isolated from the cell lysate using purification techniques known in the art, including centrifugation, depth filtration, precipitation, ultrafiltration, treatment with activated carbon, diafiltration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, and WO2008 / 118752). The purified serotype 3 capsular polysaccharide can then be used to prepare immunogenic conjugates. Isolated serotype 3 capsular polysaccharide obtained by purifying serotype 3 polysaccharide from S. pneumoniae cell lysate and optionally size fractionating the purified polysaccharide can be characterized by various parameters including, for example, weight average molecular weight (Mw). The molecular weight of polysaccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In one embodiment, the isolated serotype 3 capsular polysaccharide (i.e., purified prior to further processing) has a weight average molecular weight between 5 kDa and 5,000 kDa. In another embodiment, the isolated capsular polysaccharide has a weight average molecular weight between 100 kDa and 4,000 kDa. In a preferred embodiment, the isolated capsular polysaccharide has a weight average molecular weight between 1,000 kDa and 3,500 kDa. To produce serotype 3 conjugates with favorable filterability characteristics, immunogenicity, and / or yield, it is preferred to perform size fractionation of the polysaccharide to a target molecular weight range prior to conjugation to the carrier protein. It is desirable to reduce the size of the purified serotype 3 polysaccharide while retaining key features of the polysaccharide structure. Mechanical or chemical size fractionation may be used. In one embodiment, the size of the purified serotype 3 polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis may be performed using a weak acid (e.g., acetic acid, formic acid, propionic acid). In one embodiment, chemical hydrolysis is performed using formic acid. In one embodiment, chemical hydrolysis is performed using propionic acid. In a preferred embodiment, chemical hydrolysis is performed using acetic acid. Chemical hydrolysis may also be performed using a diluted strong acid (such as diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitric acid, or diluted perchloric acid). In one embodiment, chemical hydrolysis is performed using diluted hydrochloric acid. In one embodiment, chemical hydrolysis is performed using diluted sulfuric acid. In one embodiment, chemical hydrolysis is performed using diluted phosphoric acid. In one embodiment, chemical hydrolysis is performed using diluted nitric acid. In one embodiment, chemical hydrolysis is performed using diluted perchloric acid. The size of the purified serotype 3 polysaccharide can also be reduced by mechanical homogenization. In one embodiment, the size of the purified serotype 3 polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate is increased by using a higher applied homogenization pressure, and the exposure time can be increased by recirculating the feed stream through the homogenizer. The high-pressure homogenization process is suitable for reducing the size of the purified serotype 3 polysaccharide while retaining the structural characteristics of the polysaccharide. In one embodiment, the isolated serotype 3 capsular polysaccharide is size-fractionated to a weight average molecular weight between 5 kDa and 1000 kDa. In another embodiment, the isolated serotype 3 capsular polysaccharide is size-fractionated to a weight average molecular weight between 50 kDa and 300 kDa. In a preferred embodiment, the isolated serotype 3 capsular polysaccharide is size-fractionated to a weight average molecular weight between 100 kDa and 300 kDa. In one embodiment, the isolated serotype 3 capsular polysaccharide is size fractionated to a weight average molecular weight between about 200 kDa and about 300 kDa. In one embodiment, the isolated serotype 3 capsular polysaccharide is size fractionated to a weight average molecular weight between about 100 kDa and about 200 kDa. In one embodiment, the isolated serotype 3 capsular polysaccharide is not size fractionated. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 capsular polysaccharide, wherein the weight average molecular weight (Mw) of the polysaccharide before conjugation is between 50 kDa and 1,000 kDa, preferably between 100 kDa and 300 kDa. The weight average molecular weight (Mw) of the serotype 3 saccharide prior to conjugation refers to the Mw of the serotype 3 polysaccharide prior to activation (i.e., after the final size fractionation step but before the polysaccharide is reacted with the activating agent). In the context of the present invention, the Mw of the serotype 3 polysaccharide is not substantially modified by the activation step and the Mw of the serotype 3 polysaccharide incorporated into the conjugate is similar to the Mw of the polysaccharide measured prior to activation. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 capsular polysaccharide, wherein the weight average molecular weight (Mw) of the polysaccharide before conjugation is between 100 kDa and 200 kDa. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 capsular polysaccharide, wherein the weight average molecular weight (Mw) of the polysaccharide before conjugation is between 200 kDa and 300 kDa. In some embodiments, the serotype 3 glycoconjugates of the present invention have a weight average molecular weight (Mw) between 250 kDa and 20,000 kDa. In other embodiments, the serotype 3 glycoconjugates have a weight average molecular weight (Mw) between 500 kDa and 15,000 kDa. In still other embodiments, the serotype 3 glycoconjugates have a weight average molecular weight (Mw) between 500 kDa and 10,000 kDa. Preferably, the serotype 3 glycoconjugates have a weight average molecular weight (Mw) between 500 kDa and 5,000 kDa. In one embodiment, the serotype 3 glycoconjugate has a weight average molecular weight (Mw) between 600 kDa and 3,000 kDa. The molecular weight of polysaccharides can be measured by size exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). Another way to characterize the serotype 3 glycoconjugates of the present invention is by the presence of a carrier protein (e.g., CRM) to which the serotype 3 glycoconjugates are conjugated. 197 By determining the number of lysine residues in the carrier protein (or SCP), the saccharide can be characterized by the extent of bound lysine (degree of binding). Evidence of lysine modification of the carrier protein due to covalent linkage to the polysaccharide can be obtained by amino acid analysis using conventional methods known to those skilled in the art. Binding results in a reduction in the number of recovered lysine residues compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the degree of binding of the serotype 3 saccharide conjugates of the present invention is between 2 and 15. In preferred embodiments, the degree of conjugation of the serotype 3 glycoconjugates of the present invention is between 4 and 7. In some of these embodiments, the carrier protein is CRM 197 In other such embodiments, the carrier protein is SCP. The serotype 3 glycoconjugates of the present invention can also be characterized by the sugar to carrier protein ratio (weight / weight). In some embodiments, the serotype 3 polysaccharide to carrier protein ratio (w / w) in the glycoconjugate is between 0.5 and 3.0. In other embodiments, the sugar to carrier protein ratio (w / w) is between 0.5 and 1.5. In preferred embodiments, the serotype 3 capsular polysaccharide to carrier protein ratio in the conjugate is between 0.9 and 1.1. The serotype 3 glycoconjugates of the present invention can also be characterized by the number of covalent linkages between the carrier protein and the saccharide as a function of the saccharide repeating units. In one embodiment, the serotype 3 glycoconjugates of the present invention contain at least one covalent linkage between the carrier protein and the polysaccharide for every four saccharide repeating units of the polysaccharide. In another embodiment, the covalent linkage between the carrier protein and the polysaccharide occurs at least once for every ten saccharide repeating units of the polysaccharide. In another embodiment, the covalent linkage between the carrier protein and the polysaccharide occurs at least once for every fifteen saccharide repeating units of the polysaccharide. In a further embodiment, the covalent linkage between the carrier protein and the polysaccharide occurs at least once for every twenty-five saccharide repeating units of the polysaccharide. In a further embodiment, the covalent linkage between the carrier protein and the polysaccharide occurs at least once for every fifty saccharide repeating units of the polysaccharide. In yet a further embodiment, the covalent linkage between the carrier protein and the polysaccharide occurs at least once for every hundred saccharide repeating units of the polysaccharide. In other embodiments, the serotype 3 glycoconjugates of the present invention comprise at least one covalent linkage between the carrier protein and the polysaccharide for every 5 to 10 saccharide repeating units of the polysaccharide. In other embodiments, the serotype 3 glycoconjugates of the present invention comprise at least one covalent linkage between the carrier protein and the polysaccharide for every 10 to 20 saccharide repeating units of the polysaccharide. In some embodiments, the carrier protein is CRM 197 And between CRM 197 The covalent bond between the carrier protein and the polysaccharide occurs at least once for every 4, 10, 15, or 25 sugar repeating units of the polysaccharide. In common embodiments, the carrier protein is an SCP and the covalent bond between the SCP and the polysaccharide occurs at least once for every 4, 10, 15, or 25 sugar repeating units of the polysaccharide. The serotype 3 glycoconjugates and immunogenic compositions of the present invention may contain free saccharides that are not covalently bound to a carrier protein but are still present in the glycoconjugate composition. The free saccharides may be non-covalently associated with the glycoconjugate (i.e., non-covalently bound to, adsorbed to, or embedded in or with the glycoconjugate). In a preferred embodiment, the serotype 3 glycoconjugate comprises less than about 50% free serotype 3 polysaccharide, compared to the total amount of serotype 3 polysaccharide. In a more preferred embodiment, the serotype 3 glycoconjugate comprises less than about 40% free serotype 3 polysaccharide, compared to the total amount of serotype 3 polysaccharide. In a still more preferred embodiment, the serotype 3 glycoconjugate comprises less than about 25% free serotype 3 polysaccharide, compared to the total amount of serotype 3 polysaccharide. In an even more preferred embodiment, the serotype 3 glycoconjugate comprises less than about 20% free serotype 3 polysaccharide, compared to the total amount of serotype 3 polysaccharide. In an even more preferred embodiment, the serotype 3 glycoconjugate comprises less than about 15% free serotype 3 polysaccharide, compared to the total amount of serotype 3 polysaccharide. Serotype 3 glycoconjugates can also be characterized by their molecular size distribution (K d ) characterization. Size exclusion chromatography medium (CL-4B) can be used to determine the relative molecular size distribution of conjugates. Size exclusion chromatography (SEC) is used in gravity-fed columns to derive the molecular size distribution profile of conjugates. Large molecules, excluded from the pores in the medium, elute faster than small molecules. The column eluate is collected using a fraction collector. The eluate is colorimetrically tested using the sugar assay. Calibration is used to determine K d The column was used to establish the fraction of molecules that were completely excluded (V 0), (K d =0) and the maximum retained fraction (V i ), (K d =1). The fraction that achieves the specified sample properties (V e ) is calculated by the formula K d =(V e -V 0) / (V i -V 0) and K d association. In a preferred embodiment, at least 30% of the serotype 3 glycoconjugates have a K value less than or equal to 0.3 in the CL-4B column. d In a preferred embodiment, at least 40% of the glycoconjugates have a K value less than or equal to 0.3 in the CL-4B column. dIn preferred embodiments, at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85% of the serotype 3 glycoconjugates have a K value less than or equal to 0.3 in a CL-4B column. d In a preferred embodiment, at least 60% of the serotype 3 glycoconjugates have a K value less than or equal to 0.3 in the CL-4B column. d In a preferred embodiment, between 50% and 80% of the serotype 3 glycoconjugates have a K value less than or equal to 0.3 in the CL-4B column. d In a preferred embodiment, between 65% and 80% of the serotype 3 glycoconjugates have a K value less than or equal to 0.3 in the CL-4B column. d . In one embodiment, the serotype 3 glycoconjugates of the present invention are prepared using reductive amination chemistry (see WO2006110381, WO2008143709, PCT / IB2022 / 054920). According to the present invention, reductive amination involves two steps: (1) oxidation (activation) of the purified sugar, and (2) reduction of the activated sugar and the carrier protein (e.g., CRM). 197 , TT or SCP) to form glycoconjugates. As described above, size fractionation of the polysaccharide to a target molecular weight (MW) range may be performed prior to oxidation. Therefore, in one embodiment, the isolated polysaccharides are size-fractionated prior to oxidation. In one embodiment, the isolated polysaccharide is size fractionated into any one of the target molecular weight (MW) ranges defined above. In one embodiment, the isolated serotype 3 capsular polysaccharide is conjugated to a carrier protein by a process comprising the following steps: (a) reacting the isolated polysaccharide with an oxidizing agent; (b) complexing the activated polysaccharide of step (a) with a carrier protein; and (c) reacting the complexed activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. After the oxidation step (a), the polysaccharide is considered activated and is referred to as "activated polysaccharide". In one embodiment, the oxidizing agent is any oxidizing agent that oxidizes a terminal hydroxyl group to form an aldehyde. In one embodiment, the oxidizing agent is a periodate. For the purposes of the present invention, the term "periodate" includes both periodates and periodic acid; the term also includes metaperiodates (10 4 - ) and orthoperiodate (IO 6 5- ) and various salts of periodate (for example, sodium periodate and potassium periodate). In one embodiment, the oxidizing agent is periodate in the presence of a divalent cation (see WO 2008 / 143709). In one embodiment, the oxidant is periodic acid. In one embodiment, the oxidant is periodic acid in the presence of divalent cations. In one embodiment, the oxidant is periodic acid in the presence of Mg 2+ In one embodiment, the oxidant is periodic acid in the presence of Ca 2+ In one embodiment, the oxidizing agent is orthoperiodate. In one embodiment, the oxidizing agent is sodium periodate. In one embodiment, the periodate used for oxidation is metaperiodate. In one embodiment, the periodate used for oxidation is sodium metaperiodate. When the polysaccharide is reacted with periodate, the periodate oxidizes the vicinal hydroxyl groups to form carbonyl or aldehyde groups and causes the C—C bond to break. For this reason, the term "reacting the polysaccharide with periodate" includes the oxidation of vicinal hydroxyl groups with periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.01 to 2 molar equivalents of periodate. Preferably, step a) comprises reacting the polysaccharide with 0.1 to 2 molar equivalents of periodate. In one embodiment, step a) comprises reacting the polysaccharide with 0.01 to 2 molar equivalents of periodic acid. Preferably, step a) comprises reacting the polysaccharide with 0.2 to 2 molar equivalents of periodic acid. In a preferred embodiment, the degree of oxidation of the activated serotype 3 polysaccharide (also referred to as "activation degree" in this document) is between 2 and 30. In a preferred embodiment, the degree of oxidation of the activated serotype 3 polysaccharide is between 2 and 20. In one embodiment, the oxidation degree of the activated serotype 3 polysaccharide is between 2 and 8. In one embodiment, the oxidation degree of the activated serotype 3 polysaccharide is between 11 and 19. In one embodiment, the activated polysaccharide and the carrier protein are lyophilized before step b). Lyophilization preferably occurs after step a). In one embodiment, the activated polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized. In one embodiment, the activated polysaccharide is lyophilized after step a) and the carrier protein is also lyophilized, and the activated polysaccharide and the carrier protein are re-dissolved in the same solution, which serves to combine the activated polysaccharide and the carrier protein together. In one embodiment, the activated polysaccharide and the carrier protein are lyophilized separately (separate lyophilization). In one embodiment, the activated polysaccharide and the carrier protein are lyophilized together (co-lyophilization). In one embodiment, lyophilization occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, molasses, raffinose, stachyose, melezitose, polydextrose, mannitol, lactitol, and isomaltulose. In one embodiment, the sugar is selected from the group consisting of sucrose, molasses, and mannitol. In one embodiment, the sugar is sucrose, molasses, or mannitol. In one embodiment, the sugar is molasses. In one embodiment, the sugar is sucrose. In one embodiment, the initial input ratio (weight / weight) of activated serotype 3 capsular polysaccharide to carrier protein in step b) is between 4: 1 and 0.1: 1. In one embodiment, the initial input ratio (weight / weight) of activated serotype 3 capsular polysaccharide to carrier protein is between 2: 1 and 0.4: 1. In one embodiment, the reduction reaction (c) is carried out in an aqueous solvent. In one embodiment, the reduction reaction (c) is carried out in an aprotic solvent. In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Brønsted acid or a Lewis acid, an amine borane such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMe i PrN-BH 3. Benzylamine-BH 3 or 5-ethyl-2-methylpyridine borane (PEMB). In one embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In one embodiment, between 0.2 and 20 molar equivalents of reducing agent are used in step c). In one embodiment, between 0.5 and 3 molar equivalents of reducing agent are used in step c). At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH 4). In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 20 molar equivalents of sodium borohydride. In one embodiment, the end-capping is achieved by mixing the product of step c) with 1 to 3 molar equivalents of sodium borohydride. In one embodiment, the glycoconjugates of the present invention are prepared using CDI and / or CDT chemistry (see PCT / IB2022 / 054920). CDI and / or CDT chemistry involves two steps: 1) reacting the isolated sugar with CDI and / or CDT in an aprotic solvent to produce an activated sugar (activation), and (2) reacting the activated sugar with a carrier protein (e.g., CRM). 197 or SCP) to form a glycoconjugate. In one embodiment, the activating agent in step (1) is 1,1'-carbonyldiimidazole (CDI). In one embodiment, the activating agent in step (1) is 1,1'-carbonyl-di-(1,2,4-triazole) (CDT). In one embodiment, the isolated serotype 3 capsular polysaccharide is conjugated to a carrier protein by a process comprising the following steps: (a) reacting the isolated polysaccharide with CDI and / or CDT in an aprotic solvent; (b) reacting the activated polysaccharide of step (a) with a carrier protein in an aprotic solvent to form a glycoconjugate. In one embodiment, the serotype 3 glycoconjugates of the present invention are prepared using click chemistry (see, eg, PCT / IB2022 / 054914). According to the present invention, click chemistry comprises three steps: (a) reacting an isolated serotype 3 capsular polysaccharide with a carbonic acid derivative and an azido linker in an aprotic solvent to produce an activated azido polysaccharide (activation of the polysaccharide); (b) reacting a carrier protein with an agent carrying an N-hydroxysuccinimide (NHS) moiety and an alkyne group, wherein the NHS moiety reacts with an amine group to form an amide linkage, thereby obtaining an alkyne-functionalized carrier protein (activation of the carrier protein); and (c) reacting the activated azido polysaccharide of step (a) with the activated alkyne-carrier protein of step (b) by Cu 2+ reaction. +1 The glycoconjugates are formed by a mediated azide-alkyne cycloaddition reaction. After step (a), the polysaccharide is considered activated and is referred to herein as an "activated polysaccharide" or "activated azido polysaccharide." After step (b), the vector is considered activated and is referred to as "activated vector". As described above, prior to activation (a), size fractionation of the polysaccharide to a target molecular weight (MW) range may be performed. Thus, in one embodiment, the isolated polysaccharides are size fractionated prior to activation with a carbonate derivative and an azido linker. In one embodiment, the isolated polysaccharide is size fractionated into any one of the target molecular weight (MW) ranges defined above. In one embodiment, the carbonic acid derivative is 1,1'-carbonyldiimidazole (CDI) or 1,1'-carbonyl-di-(1,2,4-triazole) (CDT). Preferably, the carbonic acid derivative is 1,1'-carbonyldiimidazole (CDI). In one embodiment, the azido linker is a compound of formula (I), Wherein X is selected from the group consisting of: CH 2(CH 2) n 、(CH 2CH 2O) m CH 2CH 2. NHCO(CH 2) n 、NHCO(CH 2CH 2O) m CH 2CH 2. OCH 2(CH 2) n and O(CH 2CH 2O) m CH 2CH 2; wherein n is selected from 1 to 10 and m is selected from 1 to 4. In one embodiment, the azido linker is a compound of formula (II), . In one embodiment, the azido linker is 3-azidopropylamine. In one embodiment, the agent carrying an N-hydroxysuccinimide (NHS) moiety and an alkyne group is an agent carrying an N-hydroxysuccinimide (NHS) moiety and a terminal alkyne. In one embodiment, the agent carrying an N-hydroxysuccinimide (NHS) moiety and an alkyne group is an agent carrying an N-hydroxysuccinimide (NHS) moiety and a cycloalkyne. In one embodiment, the agent carrying an N-hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (III), Wherein X is selected from the group consisting of: CH 2O(CH 2) n CH 2C=O and CH 2O(CH 2CH 2O) m (CH 2) n CH 2C=O, wherein n is selected from 0 to 10 and m is selected from 0 to 4. In one embodiment, the agent carrying an N-hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (IV), . In one embodiment, step a) comprises reacting a polysaccharide with a carbonic acid derivative, and then reacting the polysaccharide activated by the carbonic acid derivative with an azido linker in an aprotic solvent to produce an activated azido polysaccharide. In one embodiment, in step a), the isolated polysaccharide is reacted with a carbonic acid derivative in an aprotic solvent. In a preferred embodiment, the isolated polysaccharide is reacted with a carbonic acid derivative in a solution consisting essentially of dimethyl sulfoxide (DMSO). In a preferred embodiment, the isolated polysaccharide is reacted with CDI in dimethyl sulfoxide (DMSO). In one embodiment, the isolated polysaccharide is reacted with CDI in anhydrous DMSO. Once the polysaccharide has been reacted with the carbonic acid derivative and after the carbonic acid derivative is finally quenched with water, the carbonic acid derivative-activated polysaccharide is reacted with an azido linker. In one embodiment, step a) further comprises reacting the polysaccharide activated with a carbonate derivative with an amount of an azide linker, wherein the amount is between 0.01 and 10 molar equivalents relative to the amount of polysaccharide repeating units (RU) of the activated polysaccharide. In one embodiment, conjugation reaction c) is performed in an aqueous buffer. In one embodiment, conjugation reaction c) is performed in an aqueous buffer in the presence of copper (I) as a catalyst. In one embodiment, conjugation reaction c) is performed in an aqueous buffer in the presence of an oxidizing agent and copper (I) as a catalyst. In a preferred embodiment, conjugation reaction c) is performed in an aqueous buffer in the presence of copper (I) as a catalyst and ascorbate as an oxidizing agent. In one embodiment, THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine may be further added to prevent side reactions of the protein. Therefore, in a preferred embodiment, conjugation reaction c) is performed in an aqueous buffer in the presence of copper (I) as a catalyst and ascorbate as an oxidizing agent, wherein the reaction mixture further comprises THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine. After the click-binding reaction, unreacted azide groups may remain in the conjugate. These azide groups can be capped using a suitable azide-capping agent. Therefore, in one embodiment, after step c), the unreacted azide groups in the conjugate are capped using a suitable azide-capping agent. In one embodiment, the azide-capping agent is an agent that carries an alkyne group. In one embodiment, the azide-capping agent is an agent that carries a terminal alkyne. In one embodiment, the azide-capping agent is an agent that carries a cycloalkyne. In one embodiment, the azide-capping agent is a compound of formula (V), Where X is (CH 2) n , wherein n is selected from 1 to 15. In one embodiment, the azide-capping agent is propargyl alcohol. Therefore, in one embodiment, after step (c), the process further comprises the step of capping the unreacted azide groups remaining in the conjugate with an azide capping agent. After the click conjugation reaction, unreacted alkyne groups may still exist in the conjugate, which can be capped using a suitable alkyne-capping agent. In one embodiment, the alkyne-capping agent is an azide-bearing agent. In one embodiment, the alkyne-capping agent is a compound of formula (VI), Where X is (CH 2) n , wherein n is selected from 1 to 15. In one embodiment, the alkyne-capping agent is 3-azido-1-propanol. Therefore, in one embodiment, after step (c), the process further comprises the step of capping the unreacted alkyne groups remaining in the conjugate with an alkyne capping agent. After conjugation to a carrier protein, the glycoconjugate can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. These techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Therefore, in one embodiment, the process for producing the glycoconjugate of the present invention includes a step of purifying the glycoconjugate after production. In one aspect, the serotype 3 glycoconjugates of the present invention are produced according to click chemistry as disclosed above and in application PCT / IB2022 / 054914, which is incorporated by reference in its entirety. Thus, in one embodiment, the serotype 3 glycoconjugates of the present invention comprise a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and have the general formula (VII): , wherein X is selected from the group consisting of: CH 2(CH 2) n’ 、(CH 2CH 2O) m CH 2CH 2. NHCO(CH 2) n’ 、NHCO(CH 2CH 2O) m CH 2CH 2. OCH 2(CH 2) n’ and O(CH 2CH 2O) m CH 2CH 2; wherein n' is selected from 1 to 10 and m is selected from 1 to 4, and wherein X' is selected from the group consisting of: CH 2O(CH 2) n’’ CH 2C=O, CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4. Formula (VII) is a schematic representation of a serotype 3 saccharide conjugate of the present invention. It should not be understood that a linkage exists on every repeating unit of the saccharide. Instead, the majority of the S. pneumoniae serotype 3 saccharide repeating units remain unmodified, and the covalent linkage between the carrier protein and the saccharide is limited to a minority of the saccharide repeating units. Furthermore, each carrier protein (CP) molecule can be linked to more than one S. pneumoniae serotype 3 saccharide molecule, and each S. pneumoniae serotype 3 saccharide molecule can be linked to more than one individual carrier protein (CP) molecule. In a preferred embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is CH 2(CH 2) n’ , wherein n' is 2, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, where n'' is 1. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is CH 2(CH 2) n’ , wherein n' is selected from 1 to 10, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, wherein n' is selected from 0 to 10. In one embodiment, n' is selected from 1 to 5 and n' is selected from 0 to 10. In one embodiment, n' is selected from 1 to 5 and n' is selected from 0 to 5. In one embodiment, n' is selected from 1 to 3 and n' is selected from 0 to 3. In one embodiment, n' is selected from 1 to 2 and n' is selected from 0 to 2. In a particular embodiment, n' is 1 and n' is 0. In another embodiment, n' is 2 and n' is 0. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is CH 2(CH 2) n’ , wherein n' is selected from 1 to 10, and wherein X' is CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is (CH 2CH 2O) m CH 2CH 2, wherein m is selected from 1 to 4, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, wherein n″ is selected from 0 to 10. In one embodiment, m is selected from 1 to 3 and n″ is selected from 0 to 10. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is (CH 2CH 2O) m CH 2CH 2, wherein m is selected from 1 to 4, and wherein X' is CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is NHCO(CH 2) n’ , wherein n' is selected from 1 to 10, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, wherein n'' is selected from 0 to 10. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is NHCO(CH 2) n’ , wherein n' is selected from 1 to 10, and wherein X' is CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is NHCO(CH 2CH 2O) m CH 2CH 2, wherein m is selected from 1 to 4, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, wherein n″ is selected from 0 to 10. In one embodiment, m is selected from 1 to 3 and n″ is selected from 0 to 10. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is NHCO(CH 2CH 2O) m CH 2CH 2, wherein m is selected from 1 to 4, and wherein X' is CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is OCH 2(CH 2) n’ , wherein n' is selected from 1 to 10, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, wherein n'' is selected from 0 to 10. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is OCH 2(CH 2) n’ , wherein n' is selected from 1 to 10, and wherein X' is CH 2O(CH 2CH 2O) m’(CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is O(CH 2CH 2O) m CH 2CH 2, wherein m is selected from 1 to 4, and wherein X' is CH 2O(CH 2) n’’ CH 2C=O, wherein n'' is selected from 0 to 10. In one embodiment, the serotype 3 saccharide conjugate of the present invention comprises a serotype 3 saccharide covalently bound to a carrier protein (CP) via a spacer and has the general formula (VII), wherein X is O(CH 2CH 2O) m CH 2CH 2, wherein m is selected from 1 to 4, and wherein X' is CH 2O(CH 2CH 2O) m’ (CH 2) n’’ CH 2C=0, wherein n'' is selected from 0 to 10 and m' is selected from 0 to 4. After conjugation to a carrier protein, serotype 3 glycoconjugates can be purified (enriched relative to the amount of glyco-protein conjugate) by various techniques known to those skilled in the art. These techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. Thus, in one embodiment, the process for producing the glycoconjugates of the present invention includes a step of purifying the glycoconjugates after production. 1.11 Carrier Protein The components of the glycoconjugate are carrier proteins that are conjugated to the S. pneumoniae saccharide. The terms "protein carrier," "carrier protein," or "carrier" are used interchangeably herein. The carrier protein should be amenable to standard conjugation procedures. In a preferred embodiment, the carrier protein of the pneumococcal glycoconjugate is selected from the group consisting of DT (diphtheria toxoid), TT (tetanus toxoid) or fragment C of TT, CRM 197 (a nontoxic but antigenically identical variant of diphtheria toxin), other DT mutants (such as CRM 176 , CRM 228 , CRM 45 (Uchida et al. (1973) J. Biol. Chem. 218: 3838-3844), CRM 9. CRM 102 , CRM 103 or CRM 107and other mutations described by Nicholls and Youle in Genetically Engineered Toxins, Ed: Frankel, Maecel Dekker Inc. (1992); deletion or mutation of Glu-148 to Asp, Gln or Ser and / or Ala 158 to Gly and other mutations disclosed in U.S. Pat. Nos. 4,709,017 and 4,950,740; mutation of at least one or more residues Lys 516, Lys 526, Phe 530 and / or Lys 534 and other mutations disclosed in U.S. Pat. Nos. 5,917,017 and 6,455,673; or fragments disclosed in U.S. Pat. No. 5,843,711), pneumolysin (ply) (Kuo et al. (1995) Infect lmmun 63: 2706-2713), including ply detoxified in some manner, such as dPLY-GMBS (WO 2004 / 081515, WO 2006 / 032499) or dPLY-formol, PhtX, including PhtA, PhtB, PhtD, PhtE (the sequences of PhtA, PhtB, PhtD or PhtE are disclosed in WO 00 / 37105 and WO 00 / 39299) and fusions of Pht proteins, such as PhtDE fusion, PhtBE fusion, Pht AE (WO 01 / 98334, WO 03 / 054007, WO 2009 / 000826), OMPC (meningococcal outer membrane protein, which is usually derived from Neisseria meningitidis ( Meningitidis) serogroup B extract) (EP0372501), PorB (from Neisseria meningitidis), PD (Haemophilus influenzae protein D; see, for example, EP0594610 B) or immunologically functional equivalents thereof, synthetic peptides (EP0378881, EP0427347), heat shock proteins (WO 93 / 17712, WO 94 / 03208), pertussis proteins (WO 98 / 58668, EP0471177), cytokines, lymphomediators, growth factors or hormones (WO 91 / 01146), artificial proteins comprising multiple human CD4+ T cell epitopes from antigens derived from various pathogens (Falugi et al. (2001) Eur J Immunol 31:3816-3824), such as N19 protein (Baraldoi et al. (2004) Infect Immunol 72: 4884-4887), Streptococcus pneumoniae surface protein PspA (WO 02 / 091998), iron absorption protein (WO 01 / 72337), Clostridium difficile ( difficile toxin A or B (WO 00 / 61761), transferrin binding protein, Streptococcus pneumoniae adhesion protein (PsaA), recombinant Pseudomonas aeruginosa exotoxin A (particularly avirulent mutants thereof, such as exotoxin A carrying a substitution at glutamine 553 (Douglas et al. (1987) J. Bacteriol. 169(11):4967-4971). Other proteins, such as ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), or purified protein derivative of tuberculin (PPD) can also be used as carrier proteins. Other suitable carrier proteins include inactivated bacterial toxins, such as cholera toxin (e.g., as described in WO 00 / 61761). 2004 / 083251), E. coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa. Another suitable carrier protein is C5a peptidase (SCP) from Streptococcus. Another suitable carrier protein is Rhizobium avidin [aa 45-179J-GGGGSSS-SP1500-AAA-SP0785] (CP1) (WO2020056202). In a preferred embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is selected from the group consisting of: TT, DT, DT mutants (such as CRM 197 ) and C5a peptidase (SCP) from Streptococcus. In one embodiment, the carrier protein of the pneumococcal glycoconjugate is DT (diphtheria toxoid). In another embodiment, the carrier protein of the pneumococcal glycoconjugate is TT (tetanus toxoid). In another embodiment, the carrier protein of the S. pneumoniae glycoconjugate is PD (Haemophilus influenzae protein D; see, for example, EP 0594610 B). In a preferred embodiment, the carrier protein of the pneumococcal glycoconjugate is CRM 197 or C5a peptidase (SCP) from Streptococcus. In another embodiment, the carrier protein of the S. pneumoniae glycoconjugate is rhizobium avidin [aa 45-179J-GGGGSSS-SP1500-AAA-SP0785] (CP1). In a preferred embodiment, part or all of the pneumococcal saccharide conjugates of the present invention are combined with CRM 197 Protein binding. CRM 197 The protein is a non-toxic form of diphtheria toxin, but is immunologically indistinguishable from diphtheria toxin. CRM 197 Non-toxigenic phage β197 tox- Infection with Corynebacterium diphtheriae ( The non-toxigenic phage system is produced by the nitrosoguanidine mutation of toxigenic corynephage β (Uchida et al. (1971) Nature New Biology 233: 8-11). 197 The protein has the same molecular weight as diphtheria toxin but differs from diphtheria toxin by a single base change in the structural gene (guanine to adenine). This single base change causes an amino acid substitution in the mature protein (glutamine to glycine) and eliminates the toxic properties of diphtheria toxin. CRM 197 Proteins are safe and effective T cell-dependent carriers of sugars. About CRM 197 Further details of the invention and its production can be found in, for example, US Pat. No. 5,614,382. In one embodiment, part or all of the pneumococcal saccharide conjugates of the present invention are combined with CRM 197In one embodiment, part or all of the pneumococcal saccharide conjugates of the present invention are conjugated to CRM 197 Protein or CRM 197 In one embodiment, part or all of the pneumococcal saccharide conjugates of the present invention are conjugated to a CRM expressed by genetically recombinant Escherichia coli. 197 The A chain is combined with (see CN103495161). In other preferred embodiments, the carrier protein of part or all of the pneumococcal glycoconjugates of the present invention is SCP (Streptococcal C5a peptidase). See WO2022249106, particularly pages 95 to 111, which are incorporated by reference. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is SCP from GBS (SCPB). An example of SCPB is provided in SEQ ID NO: 3 of WO 97 / 26008. See also SEQ ID NO: 3 of WO 00 / 34487. In another preferred embodiment, the carrier protein of the Streptococcus pneumoniae glycoconjugate of the present invention is SCP (SCPA) from GAS. Examples of SCPA can be found in SEQ. ID. No. 1 and SEQ. ID. No. 2 of WO 97 / 26008. See also SEQ ID NOs: 1, 2 and 23 of WO 00 / 34487. In a preferred embodiment, the carrier protein of the Streptococcus pneumoniae glycoconjugate of the present invention is non-enzymatically active SCP. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a fragment of SCP. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a fragment of SCPA. Preferably, the carrier protein of the pneumococcal glycoconjugate of the present invention is a fragment of SCPB. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a fragment of SCP, which comprises a protease domain, a protease-associated domain (PA domain), and three fibronectin type III (Fn) domains, but does not comprise an export signal presequence, a prosequence, and a cell wall anchor domain. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a fragment of SCP, which comprises a protease domain, a protease-associated domain (PA domain), and three fibronectin type III (Fn) domains, but does not comprise an export signal presequence, a prosequence, and a cell wall anchor domain. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a non-enzymatically active fragment of SCP, which comprises a protease domain, a protease-associated domain (PA domain), and two of the three fibronectin type III (Fn) domains, but does not comprise an export signal presequence, a prosequence, and a cell wall anchor domain. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a non-enzymatically active fragment of SCP. In one embodiment, the non-enzymatically active fragment of SCP comprises a protease domain, a protease-associated domain (PA domain), and three fibronectin type III (Fn) domains, but does not comprise an export signal presequence, a prosequence, or a cell wall anchor domain. In one embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a non-enzymatically active fragment of SCPA. In one embodiment, the non-enzymatically active fragment of SCPA comprises a protease domain, a protease-associated domain (PA domain), and three fibronectin type III (Fn) domains, but does not comprise an export signal presequence, a prosequence, or a cell wall anchor domain. In a preferred embodiment, the carrier protein of the pneumococcal glycoconjugate of the present invention is a non-enzymatically active fragment of SCPB. The non-enzymatically active fragment of SCPB preferably comprises a protease domain, a protease-associated domain (PA domain), and three fibronectin type III (Fn) domains, but does not comprise an export signal presequence, a prosequence, or a cell wall anchor domain. In one embodiment, the enzymatic activity of SCP is inactivated by replacing at least one amino acid in the wild-type sequence. In one embodiment, the replacement is selected from the group consisting of D130A, H193A, N295A, and S512A. Numbers indicate the amino acid residue positions in the peptidase according to the numbering of SEQ ID NO: 1 of WO 00 / 34487. Therefore, in one embodiment, the carrier protein of the Streptococcus pneumoniae glycoconjugate of the present invention is an enzymatically inactive SCP, wherein the inactivation is achieved by replacing at least one amino acid in the wild-type sequence. The at least one amino acid replacement is preferably in the protease domain. In one embodiment, the at least one amino acid replacement is in portion 1 of the protease domain. In one embodiment, the at least one amino acid replacement is in portion 2 of the protease domain. In one embodiment, the replacement is selected from the group consisting of D130A, H193A, N295A, and S512A. In one embodiment, the replacement is D130A. In another embodiment, the replacement is H193A. In another embodiment, the replacement is N295A. In yet another embodiment, the replacement is S512A. In one embodiment, the carrier protein of the Streptococcus pneumoniae glycoconjugate of the present invention is non-enzymatically active SCPA, wherein the inactivation is achieved by replacing at least one amino acid in the wild-type sequence. The at least one amino acid replacement is preferably in the protease domain. In one embodiment, the at least one amino acid replacement is in portion 1 of the protease domain. In one embodiment, the at least one amino acid replacement is in portion 2 of the protease domain. In one embodiment, the replacement is selected from the group consisting of D130A, H193A, N295A, and S512A. In one embodiment, the replacement is D130A. In another embodiment, the replacement is H193A. In another embodiment, the replacement is N295A. In yet another embodiment, the replacement is S512A. In one embodiment, the carrier protein of the Streptococcus pneumoniae glycoconjugate of the present invention is non-enzymatically active SCPB, wherein the inactivation is achieved by replacing at least one amino acid in the wild-type sequence. The at least one amino acid replacement is preferably in the protease domain. In one embodiment, the at least one amino acid replacement is in portion 1 of the protease domain. In one embodiment, the at least one amino acid replacement is in portion 2 of the protease domain. In one embodiment, the replacement is selected from the group consisting of D130A, H193A, N295A, and S512A. In one embodiment, the replacement is D130A. In another embodiment, the replacement is H193A. In another embodiment, the replacement is N295A. In yet another embodiment, the replacement is S512A. In one embodiment, the carrier protein of the Streptococcus pneumoniae glycoconjugate of the present invention is an enzymatically inactive fragment of SCP, wherein the inactivation is achieved by replacing at least one amino acid in the wild-type sequence. The at least one amino acid replacement is preferably in the protease domain. In one embodiment, the at least one amino acid replacement is in portion 1 of the protease domain. In one embodiment, the at least one amino acid replacement is in portion 2 of the protease domain. In one embodiment, the replacement is selected from the group consisting of D130A, H193A, N295A, and S512A. In one embodiment, the replacement is D130A. In another embodiment, the replacement is H193A. In another embodiment, the replacemen...
Claims
1. An immunogenic composition comprising a glycoconjugate of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F and a saponin-containing liposome adjuvant, the liposome adjuvant comprising a liposome composition containing monophosphatidyllipid A (MPLA) and at least one saponin, wherein the liposome composition comprises i) a lipid bilayer containing phospholipids and ii) cholesterol, wherein the saponin-containing liposome adjuvant comprises about 0.2 to about 0.8 mg / mL of monophosphatidyllipid A (MPLA), about 0.1 to about 0.4 mg / mL of QS-21, about 7 to about 28 mg / mL of DMPC, about 0.8 to about 3.2 mg / mL of DMPG and about 5.5 to about 22 mg / mL of cholesterol in phosphate buffer.
2. The immunogenic component as claimed in claim 1, wherein MPLA is monophosphatidyl-3-deacetylated lipid A.
3. The immunogenic component as claimed in claim 1, wherein the saponin-containing liposome adjuvant comprises about 0.4 mg / mL of monophosphatidyl-3-deacetylated lipid A, about 0.2 mg / mL of QS-21, about 14 mg / mL of DMPC, about 1.6 mg / mL of DMPG and about 11 mg / mL of cholesterol.
4. The immunogenic component as claimed in claim 1, wherein the saponin-containing liposome adjuvant comprises about 0.8 mg / mL of monophosphatidyl-3-deacetylated lipid A, about 0.4 mg / mL of QS-21, about 28 mg / mL of DMPC, about 3.2 mg / mL of DMPG and about 22 mg / mL of cholesterol.
5. The immunogenic component as claimed in claim 1, wherein the saponin-containing liposome adjuvant comprises about 0.2 mg / mL of monophosphatidyl-3-deacetylated lipid A, about 0.1 mg / mL of QS-21, about 7 mg / mL of DMPC, about 0.8 mg / mL of DMPG and about 5.5 mg / mL of cholesterol.
6. An immunogenic component as claimed in any of claims 1 to 5, wherein the saponin-containing liposome adjuvant is homogeneous.
7. An immunogenic component as claimed in any of claims 1 to 5, wherein the saponin-containing liposome adjuvant is heterogeneous.
8. An immune-inducing component as claimed in any of claims 1 to 5, comprising a glycoconjugate of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B.
9. An immunogenic component as claimed in any of claims 1 to 5, comprising glycoconjugates of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B, and additionally comprising at least ten glycoconjugates of Streptococcus pneumoniae serotypes 2, 6C, 7C, 7F, 9N, 10B, 15C, 16F, 17F, 20A, 20B, 21, 22A, 24B, 27, 29, 31, 33B, 34, 35F, 38, 72, and 73.
10. The immune-inducing composition as requested in item 9, which is a 35-valent pneumococcal conjugate composition.
11. An immunogenic component of any of claims 1 to 5, which is used as a medicine.
12. An immune-inducing component of any of claims 1 to 5 is used as a vaccine.
Citation Information
Patent Citations
Novel composition
TW200730189A
